<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03456960</url>
  </required_header>
  <id_info>
    <org_study_id>TAK-438ASA-1001</org_study_id>
    <secondary_id>U1111-1208-7631</secondary_id>
    <secondary_id>JapicCTI-183885</secondary_id>
    <nct_id>NCT03456960</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Bioequivalence (BE) and the Food Effect of TAK-438ASA Tablet</brief_title>
  <official_title>A Phase 1, Randomized, Open-Label, Crossover Study to Evaluate the Bioequivalence of Single Oral Dose of TAK-438ASA Tablet and Single Oral Dose of TAK-438 Tablet Plus Aspirin Enteric-Coated Tablet (Study 1) and the Food Effect of Single Oral Dose of TAK-438ASA Tablet (Study 2) in Healthy Adult Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Takeda</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Takeda</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purposes of this study are to evaluate BE between a single-dose of TAK-438ASA tablet
      versus a single-dose combination of TAK-438 tablet 10 milligram (mg) and aspirin
      enteric-coated tablet 100 mg in Japanese healthy adult men (Study 1), and to evaluate the
      effects of food on the pharmacokinetics of TAK-438ASA tablet in Japanese healthy adult men
      (Study 2).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The drug under investigation in this study is called TAK-438ASA. TAK-438ASA is being tested
      in Japanese healthy adult men. This study consists of two studies to evaluate bioequivalence
      (Study 1) and the effects of food (Study 2). Study 1 (split into a Pilot phase and a Pivotal
      phase) will look at bioequivalence between a single-dose of TAK-438ASA tablet versus a
      single-dose combination of TAK-438 tablet 10 mg and aspirin enteric-coated tablet 100 mg.
      Study 2 will look at the effects of food on the pharmacokinetics of TAK-438ASA tablet.

      The study will enroll up to 440 participants in total (Study 1 + 2). For Study 1, 12
      participants per group (24 participants in total) will be randomly assigned (by chance, like
      flipping a coin) to one of the two treatment groups for the pilot study to estimate the
      sample size of Pivotal study. After pilot study, 202 participants as a maximum per group (404
      participants in total) will be randomly assigned to one of the two treatment groups:

        -  TAK-438ASA tablet (Period 1) + TAK-438 10 mg tablet and Aspirin 100 mg tablet (Period 2)

        -  TAK-438 10 mg tablet and Aspirin 100 mg tablet (Period 1) + TAK-438ASA tablet (Period 2)

      For Study 2, 6 participants per group (12 participants in total) will be randomly assigned
      (by chance, like flipping a coin) to one of the two treatment groups:

        -  TAK-438ASA tablet (Fasted condition) + TAK-438ASA tablet (Fed condition)

        -  TAK-438ASA tablet (Fed condition) + TAK-438ASA tablet (Fasted condition) This
           single-center trial will be conducted in Japan. The overall time to participate in this
           study is approximately 18 days. Participants will make two visits to the clinic and be
           hospitalized for eight days in total.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 8, 2018</start_date>
  <completion_date type="Actual">October 12, 2018</completion_date>
  <primary_completion_date type="Actual">October 10, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Study 1, AUClast: Area Under the Plasma Concentration-time Curve From Time 0 to the Time of the Last Quantifiable Concentration for Free Base of TAK-438 (TAK-438F)</measure>
    <time_frame>Day 1 pre-dose and at multiple time points (up to 48 hours) post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Study 1, Cmax: Maximum Observed Plasma Concentration for TAK-438F</measure>
    <time_frame>Day 1 pre-dose and at multiple time points (up to 48 hours) post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Study 1, AUClast: Area Under the Plasma Concentration-time Curve From Time 0 to the Time of the Last Quantifiable Concentration for Unchanged Aspirin</measure>
    <time_frame>Day 1 pre-dose and at multiple time points (up to 12 hours) post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Study 1, Cmax: Maximum Observed Plasma Concentration for Unchanged Aspirin</measure>
    <time_frame>Day 1 pre-dose and at multiple time points (up to 12 hours) post-dose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Study 1, AUC∞: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for TAK-438F</measure>
    <time_frame>Day 1 pre-dose and at multiple time points (up to 48 hours) post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Study 1, Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for TAK-438F</measure>
    <time_frame>Day 1 pre-dose and at multiple time points (up to 48 hours) post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Study 1, MRT (Infinity,ev): Mean Residence Time From Time 0 to Infinity for TAK-438F</measure>
    <time_frame>Day 1 pre-dose and at multiple time points (up to 48 hours) post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Study 1, Lambda (z): Terminal Disposition Phase Rate Constant for TAK-438F</measure>
    <time_frame>Day 1 pre-dose and at multiple time points (up to 48 hours) post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Study 1, AUC∞: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for Unchanged Aspirin</measure>
    <time_frame>Day 1 pre-dose and at multiple time points (up to 12 hours) post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Study 1, Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for Unchanged Aspirin</measure>
    <time_frame>Day 1 pre-dose and at multiple time points (up to 12 hours) post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Study 1, MRT (Infinity,ev): Mean Residence Time From Time 0 to Infinity for Unchanged Aspirin</measure>
    <time_frame>Day 1 pre-dose and at multiple time points (up to 12 hours) post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Study 1, Lambda (z): Terminal Disposition Phase Rate Constant for Unchanged Aspirin</measure>
    <time_frame>Day 1 pre-dose and at multiple time points (up to 12 hours) post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Study 2, AUC∞: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for TAK-438F and Its Metabolites (M) (M-I, M-II, M-III and M-IV-Sul)</measure>
    <time_frame>Day 1 pre-dose and at multiple time points (up to 48 hours) post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Study 2, AUC(0-48): Area Under the Plasma Concentration-time Curve From Time 0 to Time 48 Hours Over the Dosing Interval for TAK-438F and Its Metabolites (M-I, M-II, M-III and M-IV-Sul)</measure>
    <time_frame>Day 1 pre-dose and at multiple time points (up to 48 hours) post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Study 2, AUClast: Area Under the Plasma Concentration-time Curve From Time 0 to the Time of the Last Quantifiable Concentration for TAK-438F and Its Metabolites (M-I, M-II, M-III and M-IV-Sul)</measure>
    <time_frame>Day 1 pre-dose and at multiple time points (up to 48 hours) post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Study 2, Cmax: Maximum Observed Plasma Concentration for TAK-438F and Its Metabolites (M-I, M-II, M-III and M-IV-Sul)</measure>
    <time_frame>Day 1 pre-dose and at multiple time points (up to 48 hours) post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Study 2, Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for TAK-438F and Its Metabolites (M-I, M-II, M-III and M-IV-Sul)</measure>
    <time_frame>Day 1 pre-dose and at multiple time points (up to 48 hours) post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Study 2, T1/2z: Terminal Disposition Phase Half-life for TAK-438F and Its Metabolites (M-I, M-II, M-III and M-IV-Sul)</measure>
    <time_frame>Day 1 pre-dose and at multiple time points (up to 48 hours) post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Study 2, AUC∞: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for Unchanged Aspirin and Its Metabolite (Salicylic Acid)</measure>
    <time_frame>Day 1 pre-dose and at multiple time points (up to 24 hours) post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Study 2, AUC(0-24): Area Under the Plasma Concentration-time Curve From Time 0 to Time 24 Hours Over the Dosing Interval for Unchanged Aspirin and Its Metabolite (Salicylic Acid)</measure>
    <time_frame>Day 1 pre-dose and at multiple time points (up to 24 hours) post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Study 2, AUClast: Area Under the Plasma Concentration-time Curve From Time 0 to the Time of the Last Quantifiable Concentration for Unchanged Aspirin and Its Metabolite (Salicylic Acid)</measure>
    <time_frame>Day 1 pre-dose and at multiple time points (up to 24 hours) post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Study 2, Cmax: Maximum Observed Plasma Concentration for Unchanged Aspirin and Its Metabolite (Salicylic Acid)</measure>
    <time_frame>Day 1 pre-dose and at multiple time points (up to 24 hours) post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Study 2, Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for Unchanged Aspirin and Its Metabolite (Salicylic Acid)</measure>
    <time_frame>Day 1 pre-dose and at multiple time points (up to 24 hours) post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Study 2, T1/2z: Terminal Disposition Phase Half-life for Unchanged Aspirin and Its Metabolite (Salicylic Acid)</measure>
    <time_frame>Day 1 pre-dose and at multiple time points (up to 24 hours) post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Study 2, Ae(0-48): Amount of Drug Excreted in Urine From Time 0 to 48 Hours for TAK-438F and Its Metabolites (M-I, M-II, M-III, and M-IV-Sul)</measure>
    <time_frame>Day 1 pre-dose and at multiple time points (up to 48 hours) post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Study 2, Fe(0-48): Fraction of Administered Dose Excreted Into Urine From Time 0 to Time 48 Hours for TAK-438F and Its Metabolites (M-I, M-II, M-III and M-IV-Sul)</measure>
    <time_frame>Day 1 pre-dose and at multiple time points (up to 48 hours) post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Study 2, CLR: Renal Clearance for TAK-438F and Its Metabolites (M-I, M-II, M-III, and M-IV-Sul)</measure>
    <time_frame>Day 1 pre-dose and at multiple time points (up to 48 hours) post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Study 2, Ae(0-24): Amount of Drug Excreted in Urine From Time 0 to 24 Hours for Unchanged Aspirin and Its Metabolites (Salicylic Acid and Salicyluric Acid)</measure>
    <time_frame>Day 1 pre-dose and at multiple time points (up to 24 hours) post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Study 2, Fe(0-24): Fraction of Administered Dose Excreted Into Urine From Time 0 to Time 24 Hours for Unchanged Aspirin and Its Metabolites (Salicylic Acid and Salicyluric Acid)</measure>
    <time_frame>Day 1 pre-dose and at multiple time points (up to 24 hours) post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Study 2, CLR: Renal Clearance for Unchanged Aspirin and Its Metabolites (Salicylic Acid and Salicyluric Acid)</measure>
    <time_frame>Day 1 pre-dose and at multiple time points (up to 24 hours) post-dose</time_frame>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">276</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>Pilot phase of Study 1,TAK-438ASA + TAK-438 and Aspirin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One TAK-438ASA tablet, orally without breakfast, on Day 1 of Period 1 in the Pilot phase of Study 1 (Day 1), followed by a washout period (Days 2 to 15), followed by one TAK-438 10 mg tablet and one aspirin 100 mg tablet, orally without breakfast, on Day 1 of Period 2 in the Pilot phase of Study 1 (Day 16).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pilot phase of Study 1,TAK-438 and Aspirin + TAK-438ASA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One TAK-438 10 mg tablet and one aspirin 100 mg tablet, orally without breakfast, on Day 1 of Period 1 in the Pilot phase of Study 1 (Day 1), followed by a washout period (Days 2 to 15), followed by, one TAK-438ASA tablet, orally without breakfast, on Day 1 of Period 2 in the Pilot phase of Study 1 (Day 16).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pivotal phase of Study 1, TAK-438ASA + TAK-438 and Aspirin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One TAK-438ASA tablet, orally without breakfast, on Day 1 of Period 1 in the Pivotal phase of Study 1 (Day 1), followed by a washout period (Days 2 to 15), followed by one TAK-438 10 mg tablet and one aspirin 100 mg tablet, orally without breakfast, on Day 1 of Period 2 in the Pivotal phase of Study 1 (Day 16).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pivotal phase of Study 1, TAK-438 and Aspirin + TAK-438ASA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One TAK-438 10 mg tablet and one aspirin 100 mg tablet, orally without breakfast, on Day 1 of Period 1 in the Pivotal phase of Study 1 (Day 1), followed by a washout period (Days 2 to 15), followed by one TAK-438ASA tablet, orally without breakfast, on Day 1 of Period 2 in the Pivotal phase of Study 1 (Day 16).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Study 2,TAK-438ASA (Fasted + Fed condition)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One TAK-438ASA tablet, orally without breakfast, on Day 1 of Period 1 in Study 2 (Day 1), followed by a washout period (Days 2 to 15), followed by one TAK-438ASA tablet, orally 30 minutes after breakfast, on Day 1 of Period 2 in Study 2 (Day 16).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Study 2,TAK-438ASA (Fed + Fasted condition)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One TAK-438ASA tablet, orally 30 minutes after breakfast, on Day 1 of Period 1 in Study 2 (Day 1), followed by a washout period (Days 2 to 15), followed by one TAK-438ASA tablet, orally without breakfast, on Day 1 of Period 2 in Study 2 (Day 16).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TAK-438ASA</intervention_name>
    <description>TAK-438ASA tablet.</description>
    <arm_group_label>Pilot phase of Study 1,TAK-438 and Aspirin + TAK-438ASA</arm_group_label>
    <arm_group_label>Pilot phase of Study 1,TAK-438ASA + TAK-438 and Aspirin</arm_group_label>
    <arm_group_label>Pivotal phase of Study 1, TAK-438 and Aspirin + TAK-438ASA</arm_group_label>
    <arm_group_label>Pivotal phase of Study 1, TAK-438ASA + TAK-438 and Aspirin</arm_group_label>
    <arm_group_label>Study 2,TAK-438ASA (Fasted + Fed condition)</arm_group_label>
    <arm_group_label>Study 2,TAK-438ASA (Fed + Fasted condition)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TAK-438</intervention_name>
    <description>TAK-438 tablet.</description>
    <arm_group_label>Pilot phase of Study 1,TAK-438 and Aspirin + TAK-438ASA</arm_group_label>
    <arm_group_label>Pilot phase of Study 1,TAK-438ASA + TAK-438 and Aspirin</arm_group_label>
    <arm_group_label>Pivotal phase of Study 1, TAK-438 and Aspirin + TAK-438ASA</arm_group_label>
    <arm_group_label>Pivotal phase of Study 1, TAK-438ASA + TAK-438 and Aspirin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aspirin</intervention_name>
    <description>Aspirin enteric-coated tablet.</description>
    <arm_group_label>Pilot phase of Study 1,TAK-438 and Aspirin + TAK-438ASA</arm_group_label>
    <arm_group_label>Pilot phase of Study 1,TAK-438ASA + TAK-438 and Aspirin</arm_group_label>
    <arm_group_label>Pivotal phase of Study 1, TAK-438 and Aspirin + TAK-438ASA</arm_group_label>
    <arm_group_label>Pivotal phase of Study 1, TAK-438ASA + TAK-438 and Aspirin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. In the opinion of the investigator or sub-investigator, participants are capable of
             understanding the procedures required for the study and complying with its
             requirements.

          2. Participants sign and date an informed consent form by themselves prior to the
             initiation of any study procedures.

          3. Japanese healthy men aged greater than or equal to (&gt;=) 20 and less than or equal to
             (=&lt;) 60, inclusive, at the time of consent.

          4. Body weight &gt;=50 kilogram (kg) as well as body mass index (BMI) &gt;=18.5 kilogram per
             meter square (kg/m^2) and =&lt;25.0 kg/m^2 at screening test.

        Exclusion Criteria:

          1. Participants who received study drug within 16 weeks (112 days) prior to the start of
             study treatment in Period 1.

          2. Participants who received TAK-438 or aspirin in a previous study.

          3. Staffs at the study site and their family, or participants who depend on the
             study-related staffs at the study site (example, husband and wife, parents, children,
             brothers and sisters), or participants who may be constrained to consent to the study.

          4. Participants with uncontrolled and clinically significant neurological,
             cardiovascular, lung, hepatic, renal, metabolic, gastrointestinal, urinary or
             endocrine disease, or other abnormalities (except for diseases investigated) that
             might affect the study participation or impact the results of the study.

          5. Participants with a previous or current history of aspirin asthma (asthmatic attack
             induced by non-steroidal anti-inflammatory drugs, etc.).

          6. Participants with hypersensitivity for components of TAK-438 tablet or aspirin
             enteric-coated tablet, or salicylic acid-based products.

          7. Positive result in urinary test for illegal drug abuse at screening.

          8. Participants who have a history of illegal drug abuse or alcoholism within the past 2
             years prior to the screening visit, or who are not willing to refrain from alcohol
             consumption and drug use during the study period.

          9. Participants who ingested a medicine, a supplement or food forbidden to be used in
             combination during the specified time period.

         10. Participants with a current history or recent episodes (within the past 6 months) of
             gastrointestinal diseases (malabsorption, gastroesophageal reflux, peptic ulcer
             disease, erosive oesophagitis), frequent (at least once per week) heartburn or
             surgical intervention that might affect drug absorption.

         11. Participants with a history of cancer, except for basal cell carcinoma in remission
             for &gt;=5 years prior to Day 1.

         12. Positive results at screening for hepatitis B surface antigen (HBsAg), hepatitis C
             virus (HCV) antibody, human immunodeficiency virus (HIV) antibody/antigen, or
             serological test for syphilis.

         13. Participants who have difficulties in blood draw from peripheral veins.

         14. Participants who had &gt;=200 milliliter (mL) of whole blood drawn within 4 weeks (28
             days) prior to the start of study treatment in Period 1 or who had &gt;=400 mL of whole
             blood drawn within 12 weeks (84 days) prior to the start of study treatment in Period
             1.

         15. Participants who had a total of &gt;=800 mL of whole blood drawn within 52 weeks (364
             days) prior to the start of study treatment in Period 1.

         16. Participants who had blood components drawn within 2 weeks (14 days) prior to the
             start of study treatment in Period 1.

         17. Clinically significant abnormalities in electrocardiogram at screening or admission
             (Day -1).

         18. Participants with abnormal laboratory parameters suggestive of clinically significant
             underlying diseases or who have abnormal values in the following measures at
             screening: alanine aminotransferase (ALT) or aspartate aminotransferase (AST) over the
             upper limit of normal.

         19. Participants who are unlikely to comply with the protocol or deemed ineligible due to
             other reasons by the principal investigator or other investigators.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Takeda</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Fukuoka Mirai Hospital</name>
      <address>
        <city>Fukuoka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>March 1, 2018</study_first_submitted>
  <study_first_submitted_qc>March 1, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 7, 2018</study_first_posted>
  <results_first_submitted>October 9, 2019</results_first_submitted>
  <results_first_submitted_qc>October 9, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">November 4, 2019</results_first_posted>
  <last_update_submitted>November 6, 2019</last_update_submitted>
  <last_update_submitted_qc>November 6, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 19, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Drug Therapy</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Takeda makes patient-level, de-identified data sets and associated documents available for all interventional studies after applicable marketing approvals and commercial availability have been received (or program is completely terminated), an opportunity for the primary publication of the research and final report development has been allowed, and other criteria have been met as set forth in Takeda's Data Sharing Policy (see www.TakedaClinicalTrials.com for details). To obtain access, researchers must submit a legitimate academic research proposal for adjudication by an independent review panel, who will review the scientific merit of the research and the requestor's qualifications and conflict of interest that can result in potential bias. Once approved, qualified researchers who sign a data sharing agreement are provided access to these data in a secure research environment.</ipd_description>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>February 9, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/60/NCT03456960/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>July 25, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/60/NCT03456960/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants took part in the study at 1 investigative site in Japan from 8 March 2018 to 12 October 2018.</recruitment_details>
      <pre_assignment_details>Healthy male participants were enrolled in this 2-period cross-over design study to receive 1 of the 2 treatment sequences: fixed dose combination (FDC) of TAK-438 and aspirin (TAK-438ASA) or a free combination of TAK-438 and aspirin in Study 1, and to receive 1 of the 2 sequences: FDC of TAK-438ASA under fasted or fed conditions in Study 2.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Pilot Study 1, Sequence A: TAK-438ASA + TAK-438 and Aspirin</title>
          <description>TAK-438 10 milligram (mg) and aspirin 100 mg FDC (TAK-438ASA), tablet, orally, under fasted condition, once on Day 1 of Period 1, followed by a washout period of at least 14 days, further followed by TAK-438 10 mg, tablet and aspirin 100 mg, tablet (free combination), orally, under fasted condition, once on Day 1 of Period 2.</description>
        </group>
        <group group_id="P2">
          <title>Pilot Study 1, Sequence B: TAK-438 and Aspirin + TAK-438ASA</title>
          <description>TAK-438 10 mg, tablet and aspirin 100 mg, tablet (free combination), orally, under fasted condition, once on Day 1 of Period 1, followed by a washout period of at least 14 days, further followed by TAK-438 10 mg and aspirin 100 mg FDC (TAK-438ASA), tablet, orally, under fasted condition, once on Day 1 of Period 2.</description>
        </group>
        <group group_id="P3">
          <title>Pivotal Study 1, Sequence A: TAK-438ASA + TAK-438 and Aspirin</title>
          <description>TAK-438 10 mg and aspirin 100 mg FDC (TAK-438ASA), tablet, orally, under fasted condition, once on Day 1 of Period 1, followed by a washout period of at least 14 days, further followed by TAK-438 10 mg, tablet and aspirin 100 mg, tablet (free combination), orally, under fasted condition, once on Day 1 of Period 2.</description>
        </group>
        <group group_id="P4">
          <title>Pivotal Study 1, Sequence B: TAK-438 and Aspirin + TAK-438ASA</title>
          <description>TAK-438 10 mg, tablet and aspirin 100 mg, tablet (free combination), orally, under fasted condition, once on Day 1 of Period 1, followed by a washout period of at least 14 days, further followed by TAK-438 10 mg and aspirin 100 mg FDC (TAK-438ASA), tablet, orally, under fasted condition, once on Day 1 of Period 2.</description>
        </group>
        <group group_id="P5">
          <title>Study 2, Sequence C: TAK-438ASA (Fasted + Fed Condition)</title>
          <description>TAK-438 10 mg and aspirin 100 mg FDC (TAK-438ASA), tablet, orally, under fasted condition, once on Day 1 of Period 1, followed by a washout period of at least 14 days, further followed by TAK-438 10 mg and aspirin 100 mg FDC (TAK-438ASA), tablet, orally, under fed condition, once on Day 1 of Period 2.</description>
        </group>
        <group group_id="P6">
          <title>Study 2, Sequence D: TAK-438ASA (Fed + Fasted Condition)</title>
          <description>TAK-438 10 mg and aspirin 100 mg FDC (TAK-438ASA), tablet, orally, under fed condition, once on Day 1 of Period 1, followed by a washout period of at least 14 days, further followed by TAK-438 10 mg and aspirin 100 mg FDC (TAK-438ASA), tablet, orally, under fasted condition, once on Day 1 of Period 2.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Period 1 (1 Day)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="12"/>
                <participants group_id="P3" count="120"/>
                <participants group_id="P4" count="120"/>
                <participants group_id="P5" count="6"/>
                <participants group_id="P6" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="12"/>
                <participants group_id="P3" count="120"/>
                <participants group_id="P4" count="120"/>
                <participants group_id="P5" count="6"/>
                <participants group_id="P6" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Washout Period (at Least 14 Days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="12"/>
                <participants group_id="P3" count="120"/>
                <participants group_id="P4" count="120"/>
                <participants group_id="P5" count="6"/>
                <participants group_id="P6" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="12"/>
                <participants group_id="P3" count="119"/>
                <participants group_id="P4" count="118"/>
                <participants group_id="P5" count="6"/>
                <participants group_id="P6" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Period 2 (1 Day)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="12"/>
                <participants group_id="P3" count="119"/>
                <participants group_id="P4" count="118"/>
                <participants group_id="P5" count="6"/>
                <participants group_id="P6" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="12"/>
                <participants group_id="P3" count="119"/>
                <participants group_id="P4" count="117"/>
                <participants group_id="P5" count="6"/>
                <participants group_id="P6" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>The safety analysis set was defined as all participants who received at least one dose of study drug.</population>
      <group_list>
        <group group_id="B1">
          <title>Pilot Study 1, Sequence A: TAK-438ASA + TAK-438 and Aspirin</title>
          <description>TAK-438 10 milligram (mg) and aspirin 100 mg FDC (TAK-438ASA), tablet, orally, under fasted condition, once on Day 1 of Period 1, followed by a washout period of at least 14 days, further followed by TAK-438 10 mg, tablet and aspirin 100 mg, tablet (free combination), orally, under fasted condition, once on Day 1 of Period 2.</description>
        </group>
        <group group_id="B2">
          <title>Pilot Study 1, Sequence B: TAK-438 and Aspirin + TAK-438ASA</title>
          <description>TAK-438 10 mg, tablet and aspirin 100 mg, tablet (free combination), orally, under fasted condition, once on Day 1 of Period 1, followed by a washout period of at least 14 days, further followed by TAK-438 10 mg and aspirin 100 mg FDC (TAK-438ASA), tablet, orally, under fasted condition, once on Day 1 of Period 2.</description>
        </group>
        <group group_id="B3">
          <title>Pivotal Study 1, Sequence A: TAK-438ASA + TAK-438 and Aspirin</title>
          <description>TAK-438 10 mg and aspirin 100 mg FDC (TAK-438ASA), tablet, orally, under fasted condition, once on Day 1 of Period 1, followed by a washout period of at least 14 days, further followed by TAK-438 10 mg, tablet and aspirin 100 mg, tablet (free combination), orally, under fasted condition, once on Day 1 of Period 2.</description>
        </group>
        <group group_id="B4">
          <title>Pivotal Study 1, Sequence B: TAK-438 and Aspirin + TAK-438ASA</title>
          <description>TAK-438 10 mg, tablet and aspirin 100 mg, tablet (free combination), orally, under fasted condition, once on Day 1 of Period 1, followed by a washout period of at least 14 days, further followed by TAK-438 10 mg and aspirin 100 mg FDC (TAK-438ASA), tablet, orally, under fasted condition, once on Day 1 of Period 2.</description>
        </group>
        <group group_id="B5">
          <title>Study 2, Sequence C: TAK-438ASA (Fasted + Fed Condition)</title>
          <description>TAK-438 10 mg and aspirin 100 mg FDC (TAK-438ASA), tablet, orally, under fasted condition, once on Day 1 of Period 1, followed by a washout period of at least 14 days, further followed by TAK-438 10 mg and aspirin 100 mg FDC (TAK-438ASA), tablet, orally, under fed condition, once on Day 1 of Period 2.</description>
        </group>
        <group group_id="B6">
          <title>Study 2, Sequence D: TAK-438ASA (Fed + Fasted Condition)</title>
          <description>TAK-438 10 mg and aspirin 100 mg FDC (TAK-438ASA), tablet, orally, under fed condition, once on Day 1 of Period 1, followed by a washout period of at least 14 days, further followed by TAK-438 10 mg and aspirin 100 mg FDC (TAK-438ASA), tablet, orally, under fasted condition, once on Day 1 of Period 2.</description>
        </group>
        <group group_id="B7">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="12"/>
            <count group_id="B2" value="12"/>
            <count group_id="B3" value="120"/>
            <count group_id="B4" value="120"/>
            <count group_id="B5" value="6"/>
            <count group_id="B6" value="6"/>
            <count group_id="B7" value="276"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Less than (&lt;) 20 years</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="12"/>
                    <count group_id="B2" value="12"/>
                    <count group_id="B3" value="120"/>
                    <count group_id="B4" value="120"/>
                    <count group_id="B5" value="6"/>
                    <count group_id="B6" value="6"/>
                    <count group_id="B7" value="276"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 20 and 60 years</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="12"/>
                    <count group_id="B2" value="12"/>
                    <count group_id="B3" value="120"/>
                    <count group_id="B4" value="120"/>
                    <count group_id="B5" value="6"/>
                    <count group_id="B6" value="6"/>
                    <count group_id="B7" value="276"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="120"/>
                    <measurement group_id="B4" value="120"/>
                    <measurement group_id="B5" value="6"/>
                    <measurement group_id="B6" value="6"/>
                    <measurement group_id="B7" value="276"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Greater than (&gt;) 60 years</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="12"/>
                    <count group_id="B2" value="12"/>
                    <count group_id="B3" value="120"/>
                    <count group_id="B4" value="120"/>
                    <count group_id="B5" value="6"/>
                    <count group_id="B6" value="6"/>
                    <count group_id="B7" value="276"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="12"/>
                    <count group_id="B2" value="12"/>
                    <count group_id="B3" value="120"/>
                    <count group_id="B4" value="120"/>
                    <count group_id="B5" value="6"/>
                    <count group_id="B6" value="6"/>
                    <count group_id="B7" value="276"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="120"/>
                    <measurement group_id="B4" value="120"/>
                    <measurement group_id="B5" value="6"/>
                    <measurement group_id="B6" value="6"/>
                    <measurement group_id="B7" value="276"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                    <count group_id="B4" value="0"/>
                    <count group_id="B5" value="0"/>
                    <count group_id="B6" value="0"/>
                    <count group_id="B7" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Japan</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="12"/>
                    <count group_id="B2" value="12"/>
                    <count group_id="B3" value="120"/>
                    <count group_id="B4" value="120"/>
                    <count group_id="B5" value="6"/>
                    <count group_id="B6" value="6"/>
                    <count group_id="B7" value="276"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="120"/>
                    <measurement group_id="B4" value="120"/>
                    <measurement group_id="B5" value="6"/>
                    <measurement group_id="B6" value="6"/>
                    <measurement group_id="B7" value="276"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Consumption of caffeine</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Had caffeine consumption</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="12"/>
                    <count group_id="B2" value="12"/>
                    <count group_id="B3" value="120"/>
                    <count group_id="B4" value="120"/>
                    <count group_id="B5" value="6"/>
                    <count group_id="B6" value="6"/>
                    <count group_id="B7" value="276"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="23"/>
                    <measurement group_id="B4" value="18"/>
                    <measurement group_id="B5" value="2"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Had no caffeine consumption</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="12"/>
                    <count group_id="B2" value="12"/>
                    <count group_id="B3" value="120"/>
                    <count group_id="B4" value="120"/>
                    <count group_id="B5" value="6"/>
                    <count group_id="B6" value="6"/>
                    <count group_id="B7" value="276"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="97"/>
                    <measurement group_id="B4" value="102"/>
                    <measurement group_id="B5" value="4"/>
                    <measurement group_id="B6" value="5"/>
                    <measurement group_id="B7" value="221"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Consumption of alcohol</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Drank daily</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="12"/>
                    <count group_id="B2" value="12"/>
                    <count group_id="B3" value="120"/>
                    <count group_id="B4" value="120"/>
                    <count group_id="B5" value="6"/>
                    <count group_id="B6" value="6"/>
                    <count group_id="B7" value="276"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Drank a few times per week</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="12"/>
                    <count group_id="B2" value="12"/>
                    <count group_id="B3" value="120"/>
                    <count group_id="B4" value="120"/>
                    <count group_id="B5" value="6"/>
                    <count group_id="B6" value="6"/>
                    <count group_id="B7" value="276"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="9"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Drank a few times per month</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="12"/>
                    <count group_id="B2" value="12"/>
                    <count group_id="B3" value="120"/>
                    <count group_id="B4" value="120"/>
                    <count group_id="B5" value="6"/>
                    <count group_id="B6" value="6"/>
                    <count group_id="B7" value="276"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="72"/>
                    <measurement group_id="B4" value="68"/>
                    <measurement group_id="B5" value="3"/>
                    <measurement group_id="B6" value="3"/>
                    <measurement group_id="B7" value="154"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Never drank</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="12"/>
                    <count group_id="B2" value="12"/>
                    <count group_id="B3" value="120"/>
                    <count group_id="B4" value="120"/>
                    <count group_id="B5" value="6"/>
                    <count group_id="B6" value="6"/>
                    <count group_id="B7" value="276"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="38"/>
                    <measurement group_id="B4" value="40"/>
                    <measurement group_id="B5" value="3"/>
                    <measurement group_id="B6" value="3"/>
                    <measurement group_id="B7" value="94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Smoking classification</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Never smoked</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="12"/>
                    <count group_id="B2" value="12"/>
                    <count group_id="B3" value="120"/>
                    <count group_id="B4" value="120"/>
                    <count group_id="B5" value="6"/>
                    <count group_id="B6" value="6"/>
                    <count group_id="B7" value="276"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="81"/>
                    <measurement group_id="B4" value="76"/>
                    <measurement group_id="B5" value="4"/>
                    <measurement group_id="B6" value="4"/>
                    <measurement group_id="B7" value="178"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Current smoker</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="12"/>
                    <count group_id="B2" value="12"/>
                    <count group_id="B3" value="120"/>
                    <count group_id="B4" value="120"/>
                    <count group_id="B5" value="6"/>
                    <count group_id="B6" value="6"/>
                    <count group_id="B7" value="276"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="12"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ex-smoker</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="12"/>
                    <count group_id="B2" value="12"/>
                    <count group_id="B3" value="120"/>
                    <count group_id="B4" value="120"/>
                    <count group_id="B5" value="6"/>
                    <count group_id="B6" value="6"/>
                    <count group_id="B7" value="276"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="30"/>
                    <measurement group_id="B4" value="32"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Study 1, AUClast: Area Under the Plasma Concentration-time Curve From Time 0 to the Time of the Last Quantifiable Concentration for Free Base of TAK-438 (TAK-438F)</title>
        <time_frame>Day 1 pre-dose and at multiple time points (up to 48 hours) post-dose</time_frame>
        <population>The pharmacokinetic (PK) analysis set was defined as all participants who received at least one dose of study drug, who had no major protocol deviation, and whose PK data were evaluable. Samples were not collected for Pivotal Study 1 because sufficient results were available for TAK-438F from the Pilot Study 1.</population>
        <group_list>
          <group group_id="O1">
            <title>Pilot Study 1: TAK-438ASA</title>
            <description>TAK-438 10 mg and aspirin 100 mg FDC (TAK-438ASA), tablet, orally, under fasted condition, once on Day 1 of either Period 1 or 2.</description>
          </group>
          <group group_id="O2">
            <title>Pilot Study 1: TAK-438 and Aspirin</title>
            <description>TAK-438 10 mg, tablet and aspirin 100 mg, tablet (free combination), orally, under fasted condition, once on Day 1 of either Period 1 or 2.</description>
          </group>
          <group group_id="O3">
            <title>Pivotal Study 1: TAK-438ASA</title>
            <description>TAK-438 10 mg and aspirin 100 mg FDC (TAK-438ASA), tablet, orally, under fasted condition, once on Day 1 of either Period 1 or 2.</description>
          </group>
          <group group_id="O4">
            <title>Pivotal Study 1: TAK-438 and Aspirin</title>
            <description>TAK-438 10 mg, tablet and aspirin 100 mg, tablet (free combination), orally, under fasted condition, once on Day 1 of either Period 1 or 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Study 1, AUClast: Area Under the Plasma Concentration-time Curve From Time 0 to the Time of the Last Quantifiable Concentration for Free Base of TAK-438 (TAK-438F)</title>
          <population>The pharmacokinetic (PK) analysis set was defined as all participants who received at least one dose of study drug, who had no major protocol deviation, and whose PK data were evaluable. Samples were not collected for Pivotal Study 1 because sufficient results were available for TAK-438F from the Pilot Study 1.</population>
          <units>hour*nanogram per milliliter (h*ng/mL)</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92.46" spread="32.128"/>
                    <measurement group_id="O2" value="91.95" spread="31.431"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>The difference in the least square means (LSM) between study medications (TAK-438ASA tablet - concomitant administration of TAK-438 tablet and aspirin enteric-coated tablet) and the two-sided 90 percent (%) confidence interval (CI) were provided using a crossover analysis of variance (ANOVA) model. The ANOVA model included a log-transformed (natural log) analysis variable as the dependent variable, and study medication, sequence, and period as independent variables.</non_inferiority_desc>
            <param_type>LSM Difference</param_type>
            <param_value>0.0059</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.0340</ci_lower_limit>
            <ci_upper_limit>0.0458</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Study 1, Cmax: Maximum Observed Plasma Concentration for TAK-438F</title>
        <time_frame>Day 1 pre-dose and at multiple time points (up to 48 hours) post-dose</time_frame>
        <population>The PK analysis set was defined as all participants who received at least one dose of study drug, who had no major protocol deviation, and whose PK data were evaluable. Samples were not collected for Pivotal Study 1 because sufficient results were available for TAK-438F from the Pilot Study 1.</population>
        <group_list>
          <group group_id="O1">
            <title>Pilot Study 1: TAK-438ASA</title>
            <description>TAK-438 10 mg and aspirin 100 mg FDC (TAK-438ASA), tablet, orally, under fasted condition, once on Day 1 of either Period 1 or 2.</description>
          </group>
          <group group_id="O2">
            <title>Pilot Study 1: TAK-438 and Aspirin</title>
            <description>TAK-438 10 mg, tablet and aspirin 100 mg, tablet (free combination), orally, under fasted condition, once on Day 1 of either Period 1 or 2.</description>
          </group>
          <group group_id="O3">
            <title>Pivotal Study 1: TAK-438ASA</title>
            <description>TAK-438 10 mg and aspirin 100 mg FDC (TAK-438ASA), tablet, orally, under fasted condition, once on Day 1 of either Period 1 or 2.</description>
          </group>
          <group group_id="O4">
            <title>Pivotal Study 1: TAK-438 and Aspirin</title>
            <description>TAK-438 10 mg, tablet and aspirin 100 mg, tablet (free combination), orally, under fasted condition, once on Day 1 of either Period 1 or 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Study 1, Cmax: Maximum Observed Plasma Concentration for TAK-438F</title>
          <population>The PK analysis set was defined as all participants who received at least one dose of study drug, who had no major protocol deviation, and whose PK data were evaluable. Samples were not collected for Pivotal Study 1 because sufficient results were available for TAK-438F from the Pilot Study 1.</population>
          <units>nanogram per milliliter (ng/mL)</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.87" spread="5.0945"/>
                    <measurement group_id="O2" value="13.22" spread="5.0778"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>The difference in the LSM between study medications (TAK-438ASA tablet - concomitant administration of TAK-438 tablet and aspirin enteric-coated tablet) and the two-sided 90% CI were provided using a crossover ANOVA model. The ANOVA model included a log-transformed (natural log) analysis variable as the dependent variable, and study medication, sequence, and period as independent variables.</non_inferiority_desc>
            <param_type>LSM Difference</param_type>
            <param_value>0.0508</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.0079</ci_lower_limit>
            <ci_upper_limit>0.1096</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Study 1, AUClast: Area Under the Plasma Concentration-time Curve From Time 0 to the Time of the Last Quantifiable Concentration for Unchanged Aspirin</title>
        <time_frame>Day 1 pre-dose and at multiple time points (up to 12 hours) post-dose</time_frame>
        <population>The PK analysis set was defined as all participants who received at least one dose of study drug, who had no major protocol deviation, and whose PK data were evaluable.</population>
        <group_list>
          <group group_id="O1">
            <title>Pilot Study 1: TAK-438ASA</title>
            <description>TAK-438 10 mg and aspirin 100 mg FDC (TAK-438ASA), tablet, orally, under fasted condition, once on Day 1 of either Period 1 or 2.</description>
          </group>
          <group group_id="O2">
            <title>Pilot Study 1: TAK-438 and Aspirin</title>
            <description>TAK-438 10 mg, tablet and aspirin 100 mg, tablet (free combination), orally, under fasted condition, once on Day 1 of either Period 1 or 2.</description>
          </group>
          <group group_id="O3">
            <title>Pivotal Study 1: TAK-438ASA</title>
            <description>TAK-438 10 mg and aspirin 100 mg FDC (TAK-438ASA), tablet, orally, under fasted condition, once on Day 1 of either Period 1 or 2.</description>
          </group>
          <group group_id="O4">
            <title>Pivotal Study 1: TAK-438 and Aspirin</title>
            <description>TAK-438 10 mg, tablet and aspirin 100 mg, tablet (free combination), orally, under fasted condition, once on Day 1 of either Period 1 or 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Study 1, AUClast: Area Under the Plasma Concentration-time Curve From Time 0 to the Time of the Last Quantifiable Concentration for Unchanged Aspirin</title>
          <population>The PK analysis set was defined as all participants who received at least one dose of study drug, who had no major protocol deviation, and whose PK data were evaluable.</population>
          <units>h*ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="233"/>
                <count group_id="O4" value="233"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="873.5" spread="220.94"/>
                    <measurement group_id="O2" value="831.9" spread="350.69"/>
                    <measurement group_id="O3" value="912.3" spread="327.58"/>
                    <measurement group_id="O4" value="832.7" spread="323.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>Pilot Study 1: The difference in the LSM between study medications (TAK-438ASA tablet - concomitant administration of TAK-438 tablet and aspirin enteric-coated tablet) and the two-sided 90% CI were provided using a crossover ANOVA model. The ANOVA model included a log-transformed (natural log) analysis variable as the dependent variable, and study medication, sequence, and period as independent variables.</non_inferiority_desc>
            <param_type>LSM Difference</param_type>
            <param_value>0.0546</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.0941</ci_lower_limit>
            <ci_upper_limit>0.2034</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>Pivotal Study 1: The difference in the LSM between study medications (TAK-438ASA tablet - concomitant administration of TAK-438 tablet and aspirin enteric-coated tablet) and the two-sided 90% CI were provided using a crossover ANOVA model. The ANOVA model will include a log-transformed (natural log) analysis variable as the dependent variable, and study medication, sequence, and period as independent variables.</non_inferiority_desc>
            <param_type>LSM Difference</param_type>
            <param_value>0.0912</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.0399</ci_lower_limit>
            <ci_upper_limit>0.1424</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Study 1, Cmax: Maximum Observed Plasma Concentration for Unchanged Aspirin</title>
        <time_frame>Day 1 pre-dose and at multiple time points (up to 12 hours) post-dose</time_frame>
        <population>The PK analysis set was defined as all participants who received at least one dose of study drug, who had no major protocol deviation, and whose PK data were evaluable.</population>
        <group_list>
          <group group_id="O1">
            <title>Pilot Study 1: TAK-438ASA</title>
            <description>TAK-438 10 mg and aspirin 100 mg FDC (TAK-438ASA), tablet, orally, under fasted condition, once on Day 1 of either Period 1 or 2.</description>
          </group>
          <group group_id="O2">
            <title>Pilot Study 1: TAK-438 and Aspirin</title>
            <description>TAK-438 10 mg, tablet and aspirin 100 mg, tablet (free combination), orally, under fasted condition, once on Day 1 of either Period 1 or 2.</description>
          </group>
          <group group_id="O3">
            <title>Pivotal Study 1: TAK-438ASA</title>
            <description>TAK-438 10 mg and aspirin 100 mg FDC (TAK-438ASA), tablet, orally, under fasted condition, once on Day 1 of either Period 1 or 2.</description>
          </group>
          <group group_id="O4">
            <title>Pivotal Study 1: TAK-438 and Aspirin</title>
            <description>TAK-438 10 mg, tablet and aspirin 100 mg, tablet (free combination), orally, under fasted condition, once on Day 1 of either Period 1 or 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Study 1, Cmax: Maximum Observed Plasma Concentration for Unchanged Aspirin</title>
          <population>The PK analysis set was defined as all participants who received at least one dose of study drug, who had no major protocol deviation, and whose PK data were evaluable.</population>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="233"/>
                <count group_id="O4" value="233"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="647.6" spread="326.77"/>
                    <measurement group_id="O2" value="597.5" spread="507.90"/>
                    <measurement group_id="O3" value="701.8" spread="349.18"/>
                    <measurement group_id="O4" value="558.0" spread="404.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>Pilot Study 1: The difference in the LSM between study medications (TAK-438ASA tablet - concomitant administration of TAK-438 tablet and aspirin enteric-coated tablet) and the two-sided 90% CI were provided using a crossover ANOVA model. The ANOVA model included a log-transformed (natural log) analysis variable as the dependent variable, and study medication, sequence, and period as independent variables.</non_inferiority_desc>
            <param_type>LSM Difference</param_type>
            <param_value>0.0916</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.1330</ci_lower_limit>
            <ci_upper_limit>0.3162</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>Pivotal Study 1: The difference in the LSM between study medications (TAK-438ASA tablet - concomitant administration of TAK-438 tablet and aspirin enteric-coated tablet) and the two-sided 90% CI were provided using a crossover ANOVA model. The ANOVA model included a log-transformed (natural log) analysis variable as the dependent variable, and study medication, sequence, and period as independent variables.</non_inferiority_desc>
            <param_type>LSM Difference</param_type>
            <param_value>0.2293</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.1519</ci_lower_limit>
            <ci_upper_limit>0.3068</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Study 1, AUC∞: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for TAK-438F</title>
        <time_frame>Day 1 pre-dose and at multiple time points (up to 48 hours) post-dose</time_frame>
        <population>The PK analysis set included all participants who received at least one dose of study drug, who had no major protocol deviation, and whose PK data were evaluable. Samples were not collected for Pivotal Study 1 because sufficient results were available for TAK-438F from the Pilot Study 1.</population>
        <group_list>
          <group group_id="O1">
            <title>Pilot Study 1: TAK-438ASA</title>
            <description>TAK-438 10 mg and aspirin 100 mg FDC (TAK-438ASA), tablet, orally, under fasted condition, once on Day 1 of either Period 1 or 2.</description>
          </group>
          <group group_id="O2">
            <title>Pilot Study 1: TAK-438 and Aspirin</title>
            <description>TAK-438 10 mg, tablet and aspirin 100 mg, tablet (free combination), orally, under fasted condition, once on Day 1 of either Period 1 or 2.</description>
          </group>
          <group group_id="O3">
            <title>Pivotal Study 1: TAK-438ASA</title>
            <description>TAK-438 10 mg and aspirin 100 mg FDC (TAK-438ASA), tablet, orally, under fasted condition, once on Day 1 of either Period 1 or 2.</description>
          </group>
          <group group_id="O4">
            <title>Pivotal Study 1: TAK-438 and Aspirin</title>
            <description>TAK-438 10 mg, tablet and aspirin 100 mg, tablet (free combination), orally, under fasted condition, once on Day 1 of either Period 1 or 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Study 1, AUC∞: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for TAK-438F</title>
          <population>The PK analysis set included all participants who received at least one dose of study drug, who had no major protocol deviation, and whose PK data were evaluable. Samples were not collected for Pivotal Study 1 because sufficient results were available for TAK-438F from the Pilot Study 1.</population>
          <units>h*ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94.71" spread="32.334"/>
                    <measurement group_id="O2" value="93.78" spread="31.828"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>The difference in the LSM between study medications (TAK-438ASA tablet - concomitant administration of TAK-438 tablet and aspirin enteric-coated tablet) and the two-sided 90% CI were provided using a crossover ANOVA model. The ANOVA model included a log-transformed (natural log) analysis variable as the dependent variable, and study medication, sequence, and period as independent variables.</non_inferiority_desc>
            <param_type>LSM Difference</param_type>
            <param_value>0.0100</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.0299</ci_lower_limit>
            <ci_upper_limit>0.0500</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Study 1, Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for TAK-438F</title>
        <time_frame>Day 1 pre-dose and at multiple time points (up to 48 hours) post-dose</time_frame>
        <population>The PK analysis set was defined as all participants who received at least one dose of study drug, who had no major protocol deviation, and whose PK data were evaluable. Samples were not collected for Pivotal Study 1 because sufficient results were available for TAK-438F from the Pilot Study 1.</population>
        <group_list>
          <group group_id="O1">
            <title>Pilot Study 1: TAK-438ASA</title>
            <description>TAK-438 10 mg and aspirin 100 mg FDC (TAK-438ASA), tablet, orally, under fasted condition, once on Day 1 of either Period 1 or 2.</description>
          </group>
          <group group_id="O2">
            <title>Pilot Study 1: TAK-438 and Aspirin</title>
            <description>TAK-438 10 mg, tablet and aspirin 100 mg, tablet (free combination), orally, under fasted condition, once on Day 1 of either Period 1 or 2.</description>
          </group>
          <group group_id="O3">
            <title>Pivotal Study 1: TAK-438ASA</title>
            <description>TAK-438 10 mg and aspirin 100 mg FDC (TAK-438ASA), tablet, orally, under fasted condition, once on Day 1 of either Period 1 or 2.</description>
          </group>
          <group group_id="O4">
            <title>Pivotal Study 1: TAK-438 and Aspirin</title>
            <description>TAK-438 10 mg, tablet and aspirin 100 mg, tablet (free combination), orally, under fasted condition, once on Day 1 of either Period 1 or 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Study 1, Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for TAK-438F</title>
          <population>The PK analysis set was defined as all participants who received at least one dose of study drug, who had no major protocol deviation, and whose PK data were evaluable. Samples were not collected for Pivotal Study 1 because sufficient results were available for TAK-438F from the Pilot Study 1.</population>
          <units>hour</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.500" lower_limit="1.00" upper_limit="3.00"/>
                    <measurement group_id="O2" value="1.500" lower_limit="1.00" upper_limit="3.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>The difference in the LSM between study medications (TAK-438ASA tablet - concomitant administration of TAK-438 tablet and aspirin enteric-coated tablet) and the two-sided 90% CI were provided using a crossover ANOVA model. The ANOVA model included a log-transformed (natural log) analysis variable as the dependent variable, and study medication, sequence, and period as independent variables.</non_inferiority_desc>
            <param_type>LSM Difference</param_type>
            <param_value>-0.0281</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.1662</ci_lower_limit>
            <ci_upper_limit>0.1100</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Study 1, MRT (Infinity,ev): Mean Residence Time From Time 0 to Infinity for TAK-438F</title>
        <time_frame>Day 1 pre-dose and at multiple time points (up to 48 hours) post-dose</time_frame>
        <population>The PK analysis set was defined as all participants who received at least one dose of study drug, who had no major protocol deviation, and whose PK data were evaluable. Samples were not collected for Pivotal Study 1 because sufficient results were available for TAK-438F from the Pilot Study 1.</population>
        <group_list>
          <group group_id="O1">
            <title>Pilot Study 1: TAK-438ASA</title>
            <description>TAK-438 10 mg and aspirin 100 mg FDC (TAK-438ASA), tablet, orally, under fasted condition, once on Day 1 of either Period 1 or 2.</description>
          </group>
          <group group_id="O2">
            <title>Pilot Study 1: TAK-438 and Aspirin</title>
            <description>TAK-438 10 mg, tablet and aspirin 100 mg, tablet (free combination), orally, under fasted condition, once on Day 1 of either Period 1 or 2.</description>
          </group>
          <group group_id="O3">
            <title>Pivotal Study 1: TAK-438ASA</title>
            <description>TAK-438 10 mg and aspirin 100 mg FDC (TAK-438ASA), tablet, orally, under fasted condition, once on Day 1 of either Period 1 or 2.</description>
          </group>
          <group group_id="O4">
            <title>Pivotal Study 1: TAK-438 and Aspirin</title>
            <description>TAK-438 10 mg, tablet and aspirin 100 mg, tablet (free combination), orally, under fasted condition, once on Day 1 of either Period 1 or 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Study 1, MRT (Infinity,ev): Mean Residence Time From Time 0 to Infinity for TAK-438F</title>
          <population>The PK analysis set was defined as all participants who received at least one dose of study drug, who had no major protocol deviation, and whose PK data were evaluable. Samples were not collected for Pivotal Study 1 because sufficient results were available for TAK-438F from the Pilot Study 1.</population>
          <units>hour</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.610" spread="1.2440"/>
                    <measurement group_id="O2" value="9.751" spread="1.3853"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>The difference in the LSM between study medications (TAK-438ASA tablet - concomitant administration of TAK-438 tablet and aspirin enteric-coated tablet) and the two-sided 90% CI were provided using a crossover ANOVA model. The ANOVA model included a log-transformed (natural log) analysis variable as the dependent variable, and study medication, sequence, and period as independent variables.</non_inferiority_desc>
            <param_type>LSM Difference</param_type>
            <param_value>-0.0150</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.0448</ci_lower_limit>
            <ci_upper_limit>0.0149</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Study 1, Lambda (z): Terminal Disposition Phase Rate Constant for TAK-438F</title>
        <time_frame>Day 1 pre-dose and at multiple time points (up to 48 hours) post-dose</time_frame>
        <population>The PK analysis set was defined as all participants who received at least one dose of study drug, who had no major protocol deviation, and whose PK data were evaluable. Samples were not collected for Pivotal Study 1 because sufficient results were available for TAK-438F from the Pilot Study 1.</population>
        <group_list>
          <group group_id="O1">
            <title>Pilot Study 1: TAK-438ASA</title>
            <description>TAK-438 10 mg and aspirin 100 mg FDC (TAK-438ASA), tablet, orally, under fasted condition, once on Day 1 of either Period 1 or 2.</description>
          </group>
          <group group_id="O2">
            <title>Pilot Study 1: TAK-438 and Aspirin</title>
            <description>TAK-438 10 mg, tablet and aspirin 100 mg, tablet (free combination), orally, under fasted condition, once on Day 1 of either Period 1 or 2.</description>
          </group>
          <group group_id="O3">
            <title>Pivotal Study 1: TAK-438ASA</title>
            <description>TAK-438 10 mg and aspirin 100 mg FDC (TAK-438ASA), tablet, orally, under fasted condition, once on Day 1 of either Period 1 or 2.</description>
          </group>
          <group group_id="O4">
            <title>Pivotal Study 1: TAK-438 and Aspirin</title>
            <description>TAK-438 10 mg, tablet and aspirin 100 mg, tablet (free combination), orally, under fasted condition, once on Day 1 of either Period 1 or 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Study 1, Lambda (z): Terminal Disposition Phase Rate Constant for TAK-438F</title>
          <population>The PK analysis set was defined as all participants who received at least one dose of study drug, who had no major protocol deviation, and whose PK data were evaluable. Samples were not collected for Pivotal Study 1 because sufficient results were available for TAK-438F from the Pilot Study 1.</population>
          <units>1 per hour</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.08565" spread="0.0090230"/>
                    <measurement group_id="O2" value="0.08788" spread="0.013025"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>The difference in the LSM between study medications (TAK-438ASA tablet - concomitant administration of TAK-438 tablet and aspirin enteric-coated tablet) and the two-sided 90% CI were provided using a crossover ANOVA model. The ANOVA model included a log-transformed (natural log) analysis variable as the dependent variable, and study medication, sequence, and period as independent variables.</non_inferiority_desc>
            <param_type>LSM Difference</param_type>
            <param_value>-0.0195</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.0676</ci_lower_limit>
            <ci_upper_limit>0.0286</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Study 1, AUC∞: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for Unchanged Aspirin</title>
        <time_frame>Day 1 pre-dose and at multiple time points (up to 12 hours) post-dose</time_frame>
        <population>The PK analysis set was defined as all participants who received at least one dose of study drug, who had no major protocol deviation, and whose PK data were evaluable. The PK analysis set where data at specified time points was available.</population>
        <group_list>
          <group group_id="O1">
            <title>Pilot Study 1: TAK-438ASA</title>
            <description>TAK-438 10 mg and aspirin 100 mg FDC (TAK-438ASA), tablet, orally, under fasted condition, once on Day 1 of either Period 1 or 2.</description>
          </group>
          <group group_id="O2">
            <title>Pilot Study 1: TAK-438 and Aspirin</title>
            <description>TAK-438 10 mg, tablet and aspirin 100 mg, tablet (free combination), orally, under fasted condition, once on Day 1 of either Period 1 or 2.</description>
          </group>
          <group group_id="O3">
            <title>Pivotal Study 1: TAK-438ASA</title>
            <description>TAK-438 10 mg and aspirin 100 mg FDC (TAK-438ASA), tablet, orally, under fasted condition, once on Day 1 of either Period 1 or 2.</description>
          </group>
          <group group_id="O4">
            <title>Pivotal Study 1: TAK-438 and Aspirin</title>
            <description>TAK-438 10 mg, tablet and aspirin 100 mg, tablet (free combination), orally, under fasted condition, once on Day 1 of either Period 1 or 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Study 1, AUC∞: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for Unchanged Aspirin</title>
          <population>The PK analysis set was defined as all participants who received at least one dose of study drug, who had no major protocol deviation, and whose PK data were evaluable. The PK analysis set where data at specified time points was available.</population>
          <units>h*ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="231"/>
                <count group_id="O4" value="221"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="876.5" spread="221.10"/>
                    <measurement group_id="O2" value="834.6" spread="349.28"/>
                    <measurement group_id="O3" value="915.8" spread="328.82"/>
                    <measurement group_id="O4" value="855.4" spread="322.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>Pilot Study 1: The difference in the LSM between study medications (TAK-438ASA tablet - concomitant administration of TAK-438 tablet and aspirin enteric-coated tablet) and the two-sided 90% CI were provided using a crossover ANOVA model. The ANOVA model included a log-transformed (natural log) analysis variable as the dependent variable, and study medication, sequence, and period as independent variables.</non_inferiority_desc>
            <param_type>LSM Difference</param_type>
            <param_value>0.0547</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.0937</ci_lower_limit>
            <ci_upper_limit>0.2032</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>Pivotal Study 1: The difference in the LSM between study medications (TAK-438ASA tablet - concomitant administration of TAK-438 tablet and aspirin enteric-coated tablet) and the two-sided 90% CI were provided using a crossover ANOVA model. The ANOVA model included a log-transformed (natural log) analysis variable as the dependent variable, and study medication, sequence, and period as independent variables.</non_inferiority_desc>
            <param_type>LSM Difference</param_type>
            <param_value>0.0654</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.0141</ci_lower_limit>
            <ci_upper_limit>0.1167</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Study 1, Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for Unchanged Aspirin</title>
        <time_frame>Day 1 pre-dose and at multiple time points (up to 12 hours) post-dose</time_frame>
        <population>The PK analysis set was defined as all participants who received at least one dose of study drug, who had no major protocol deviation, and whose PK data were evaluable.</population>
        <group_list>
          <group group_id="O1">
            <title>Pilot Study 1: TAK-438ASA</title>
            <description>TAK-438 10 mg and aspirin 100 mg FDC (TAK-438ASA), tablet, orally, under fasted condition, once on Day 1 of either Period 1 or 2.</description>
          </group>
          <group group_id="O2">
            <title>Pilot Study 1: TAK-438 and Aspirin</title>
            <description>TAK-438 10 mg, tablet and aspirin 100 mg, tablet (free combination), orally, under fasted condition, once on Day 1 of either Period 1 or 2.</description>
          </group>
          <group group_id="O3">
            <title>Pivotal Study 1: TAK-438ASA</title>
            <description>TAK-438 10 mg and aspirin 100 mg FDC (TAK-438ASA), tablet, orally, under fasted condition, once on Day 1 of either Period 1 or 2.</description>
          </group>
          <group group_id="O4">
            <title>Pivotal Study 1: TAK-438 and Aspirin</title>
            <description>TAK-438 10 mg, tablet and aspirin 100 mg, tablet (free combination), orally, under fasted condition, once on Day 1 of either Period 1 or 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Study 1, Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for Unchanged Aspirin</title>
          <population>The PK analysis set was defined as all participants who received at least one dose of study drug, who had no major protocol deviation, and whose PK data were evaluable.</population>
          <units>hour</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="233"/>
                <count group_id="O4" value="233"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.000" lower_limit="2.50" upper_limit="8.50"/>
                    <measurement group_id="O2" value="4.500" lower_limit="3.00" upper_limit="8.50"/>
                    <measurement group_id="O3" value="4.000" lower_limit="2.00" upper_limit="11.0"/>
                    <measurement group_id="O4" value="4.500" lower_limit="1.00" upper_limit="12.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>Pilot Study 1: The difference in the LSM between study medications (TAK-438ASA tablet - concomitant administration of TAK-438 tablet and aspirin enteric-coated tablet) and the two-sided 90% CI were provided using a crossover ANOVA model. The ANOVA model included a log-transformed (natural log) analysis variable as the dependent variable, and study medication, sequence, and period as independent variables.</non_inferiority_desc>
            <param_type>LSM Difference</param_type>
            <param_value>-0.1460</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.2478</ci_lower_limit>
            <ci_upper_limit>-0.0443</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>Pivotal Study 1: The difference in the LSM between study medications (TAK-438ASA tablet - concomitant administration of TAK-438 tablet and aspirin enteric-coated tablet) and the two-sided 90% CI were provided using a crossover ANOVA model. The ANOVA model included a log-transformed (natural log) analysis variable as the dependent variable, and study medication, sequence, and period as independent variables.</non_inferiority_desc>
            <param_type>LSM Difference</param_type>
            <param_value>-0.1674</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.2084</ci_lower_limit>
            <ci_upper_limit>-0.1264</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Study 1, MRT (Infinity,ev): Mean Residence Time From Time 0 to Infinity for Unchanged Aspirin</title>
        <time_frame>Day 1 pre-dose and at multiple time points (up to 12 hours) post-dose</time_frame>
        <population>The PK analysis set was defined as all participants who received at least one dose of study drug, who had no major protocol deviation, and whose PK data were evaluable. The PK analysis set where data at specified time points was available.</population>
        <group_list>
          <group group_id="O1">
            <title>Pilot Study 1: TAK-438ASA</title>
            <description>TAK-438 10 mg and aspirin 100 mg FDC (TAK-438ASA), tablet, orally, under fasted condition, once on Day 1 of either Period 1 or 2.</description>
          </group>
          <group group_id="O2">
            <title>Pilot Study 1: TAK-438 and Aspirin</title>
            <description>TAK-438 10 mg, tablet and aspirin 100 mg, tablet (free combination), orally, under fasted condition, once on Day 1 of either Period 1 or 2.</description>
          </group>
          <group group_id="O3">
            <title>Pivotal Study 1: TAK-438ASA</title>
            <description>TAK-438 10 mg and aspirin 100 mg FDC (TAK-438ASA), tablet, orally, under fasted condition, once on Day 1 of either Period 1 or 2.</description>
          </group>
          <group group_id="O4">
            <title>Pivotal Study 1: TAK-438 and Aspirin</title>
            <description>TAK-438 10 mg, tablet and aspirin 100 mg, tablet (free combination), orally, under fasted condition, once on Day 1 of either Period 1 or 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Study 1, MRT (Infinity,ev): Mean Residence Time From Time 0 to Infinity for Unchanged Aspirin</title>
          <population>The PK analysis set was defined as all participants who received at least one dose of study drug, who had no major protocol deviation, and whose PK data were evaluable. The PK analysis set where data at specified time points was available.</population>
          <units>hour</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="231"/>
                <count group_id="O4" value="221"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.629" spread="1.4634"/>
                    <measurement group_id="O2" value="5.194" spread="1.5154"/>
                    <measurement group_id="O3" value="4.398" spread="1.0552"/>
                    <measurement group_id="O4" value="5.152" spread="2.0334"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>Pilot Study 1: The difference in the LSM between study medications (TAK-438ASA tablet - concomitant administration of TAK-438 tablet and aspirin enteric-coated tablet) and the two-sided 90% CI were provided using a crossover ANOVA model. The ANOVA model included a log-transformed (natural log) analysis variable as the dependent variable, and study medication, sequence, and period as independent variables.</non_inferiority_desc>
            <param_type>LSM Difference</param_type>
            <param_value>-0.1193</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.2179</ci_lower_limit>
            <ci_upper_limit>-0.0206</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>Pivotal Study 1: The difference in the LSM between study medications (TAK-438ASA tablet - concomitant administration of TAK-438 tablet and aspirin enteric-coated tablet) and the two-sided 90% CI were provided using a crossover ANOVA model. The ANOVA model included a log-transformed (natural log) analysis variable as the dependent variable, and study medication, sequence, and period as independent variables.</non_inferiority_desc>
            <param_type>LSM Difference</param_type>
            <param_value>-0.1366</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.1730</ci_lower_limit>
            <ci_upper_limit>-0.1002</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Study 1, Lambda (z): Terminal Disposition Phase Rate Constant for Unchanged Aspirin</title>
        <time_frame>Day 1 pre-dose and at multiple time points (up to 12 hours) post-dose</time_frame>
        <population>The PK analysis set was defined as all participants who received at least one dose of study drug, who had no major protocol deviation, and whose PK data were evaluable. The PK analysis set where data at specified time points was available.</population>
        <group_list>
          <group group_id="O1">
            <title>Pilot Study 1: TAK-438ASA</title>
            <description>TAK-438 10 mg and aspirin 100 mg FDC (TAK-438ASA), tablet, orally, under fasted condition, once on Day 1 of either Period 1 or 2.</description>
          </group>
          <group group_id="O2">
            <title>Pilot Study 1: TAK-438 and Aspirin</title>
            <description>TAK-438 10 mg, tablet and aspirin 100 mg, tablet (free combination), orally, under fasted condition, once on Day 1 of either Period 1 or 2.</description>
          </group>
          <group group_id="O3">
            <title>Pivotal Study 1: TAK-438ASA</title>
            <description>TAK-438 10 mg and aspirin 100 mg FDC (TAK-438ASA), tablet, orally, under fasted condition, once on Day 1 of either Period 1 or 2.</description>
          </group>
          <group group_id="O4">
            <title>Pivotal Study 1: TAK-438 and Aspirin</title>
            <description>TAK-438 10 mg, tablet and aspirin 100 mg, tablet (free combination), orally, under fasted condition, once on Day 1 of either Period 1 or 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Study 1, Lambda (z): Terminal Disposition Phase Rate Constant for Unchanged Aspirin</title>
          <population>The PK analysis set was defined as all participants who received at least one dose of study drug, who had no major protocol deviation, and whose PK data were evaluable. The PK analysis set where data at specified time points was available.</population>
          <units>1 per hour</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="231"/>
                <count group_id="O4" value="221"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.734" spread="0.30398"/>
                    <measurement group_id="O2" value="1.703" spread="0.30765"/>
                    <measurement group_id="O3" value="1.754" spread="0.32224"/>
                    <measurement group_id="O4" value="1.795" spread="0.35228"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>Pilot Study 1: The difference in the LSM between study medications (TAK-438ASA tablet - concomitant administration of TAK-438 tablet and aspirin enteric-coated tablet) and the two-sided 90% CI were provided using a crossover ANOVA model. The ANOVA model included a log-transformed (natural log) analysis variable as the dependent variable, and study medication, sequence, and period as independent variables.</non_inferiority_desc>
            <param_type>LSM Difference</param_type>
            <param_value>0.0148</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.0734</ci_lower_limit>
            <ci_upper_limit>0.1030</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>Pivotal Study 1: The difference in the LSM between study medications (TAK-438ASA tablet - concomitant administration of TAK-438 tablet and aspirin enteric-coated tablet) and the two-sided 90% CI were provided using a crossover ANOVA model. The ANOVA model included a log-transformed (natural log) analysis variable as the dependent variable, and study medication, sequence, and period as independent variables.</non_inferiority_desc>
            <param_type>LSM Difference</param_type>
            <param_value>-0.0020</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.0463</ci_lower_limit>
            <ci_upper_limit>0.0424</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Study 2, AUC∞: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for TAK-438F and Its Metabolites (M) (M-I, M-II, M-III and M-IV-Sul)</title>
        <time_frame>Day 1 pre-dose and at multiple time points (up to 48 hours) post-dose</time_frame>
        <population>The PK analysis set was defined as all participants who received at least one dose of study drug, who had no major protocol deviation, and whose PK data were evaluable. The PK analysis set where data at specified time points was available.</population>
        <group_list>
          <group group_id="O1">
            <title>Study 2: TAK-438ASA Fasted</title>
            <description>TAK-438 10 mg and aspirin 100 mg FDC (TAK-438ASA), tablet, orally, under fasted condition, once on Day 1 of either Period 1 or 2.</description>
          </group>
          <group group_id="O2">
            <title>Study 2: TAK-430ASA Fed</title>
            <description>TAK-438 10 mg and aspirin 100 mg FDC (TAK-438ASA), tablet, orally, under fed condition, once on Day 1 of either Period 1 or 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Study 2, AUC∞: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for TAK-438F and Its Metabolites (M) (M-I, M-II, M-III and M-IV-Sul)</title>
          <population>The PK analysis set was defined as all participants who received at least one dose of study drug, who had no major protocol deviation, and whose PK data were evaluable. The PK analysis set where data at specified time points was available.</population>
          <units>h*ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>TAK-438F</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84.26" spread="16.890"/>
                    <measurement group_id="O2" value="104.3" spread="19.470"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M-I</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="290.4" spread="50.706"/>
                    <measurement group_id="O2" value="266.9" spread="44.125"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M-II</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.77" spread="19.175"/>
                    <measurement group_id="O2" value="58.29" spread="63.088"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M-III</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83.59" spread="15.202"/>
                    <measurement group_id="O2" value="80.25" spread="22.318"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M-IV-Sul</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="115.9" spread="37.933"/>
                    <measurement group_id="O2" value="97.60" spread="40.882"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>TAK-438F: The difference in the LSM between dosing condition (TAK-438ASA tablet taken in a fed [30 minutes after starting breakfast] - TAK-438ASA tablet taken in a fasted [without breakfast] condition) and the two-sided 90% CI were provided using a crossover ANOVA model. The ANOVA model included a log-transformed (natural log) analysis variable as the dependent variable, and dosing condition, sequence, and period as independent variables.</non_inferiority_desc>
            <param_type>LSM Difference</param_type>
            <param_value>0.2138</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.1609</ci_lower_limit>
            <ci_upper_limit>0.2667</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Study 2, AUC(0-48): Area Under the Plasma Concentration-time Curve From Time 0 to Time 48 Hours Over the Dosing Interval for TAK-438F and Its Metabolites (M-I, M-II, M-III and M-IV-Sul)</title>
        <time_frame>Day 1 pre-dose and at multiple time points (up to 48 hours) post-dose</time_frame>
        <population>The PK analysis set was defined as all participants who received at least one dose of study drug, who had no major protocol deviation, and whose PK data were evaluable.</population>
        <group_list>
          <group group_id="O1">
            <title>Study 2: TAK-438ASA Fasted</title>
            <description>TAK-438 10 mg and aspirin 100 mg FDC (TAK-438ASA), tablet, orally, under fasted condition, once on Day 1 of either Period 1 or 2.</description>
          </group>
          <group group_id="O2">
            <title>Study 2: TAK-430ASA Fed</title>
            <description>TAK-438 10 mg and aspirin 100 mg FDC (TAK-438ASA), tablet, orally, under fed condition, once on Day 1 of either Period 1 or 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Study 2, AUC(0-48): Area Under the Plasma Concentration-time Curve From Time 0 to Time 48 Hours Over the Dosing Interval for TAK-438F and Its Metabolites (M-I, M-II, M-III and M-IV-Sul)</title>
          <population>The PK analysis set was defined as all participants who received at least one dose of study drug, who had no major protocol deviation, and whose PK data were evaluable.</population>
          <units>h*ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>TAK-438F</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82.89" spread="16.467"/>
                    <measurement group_id="O2" value="102.9" spread="18.851"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M-I</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="272.1" spread="49.341"/>
                    <measurement group_id="O2" value="251.9" spread="44.461"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M-II</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.80" spread="14.808"/>
                    <measurement group_id="O2" value="24.17" spread="12.927"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M-III</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82.96" spread="14.931"/>
                    <measurement group_id="O2" value="79.69" spread="22.117"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M-IV-Sul</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="111.5" spread="38.376"/>
                    <measurement group_id="O2" value="93.20" spread="41.338"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>TAK-438F: The difference in the LSM between dosing condition (TAK-438ASA tablet taken in a fed [30 minutes after starting breakfast] - TAK-438ASA tablet taken in a fasted [without breakfast] condition) and the two-sided 90% CI were provided using a crossover ANOVA model. The ANOVA model included a log-transformed (natural log) analysis variable as the dependent variable, and dosing condition, sequence, and period as independent variables.</non_inferiority_desc>
            <param_type>LSM Difference</param_type>
            <param_value>0.2161</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.1652</ci_lower_limit>
            <ci_upper_limit>0.2671</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Study 2, AUClast: Area Under the Plasma Concentration-time Curve From Time 0 to the Time of the Last Quantifiable Concentration for TAK-438F and Its Metabolites (M-I, M-II, M-III and M-IV-Sul)</title>
        <time_frame>Day 1 pre-dose and at multiple time points (up to 48 hours) post-dose</time_frame>
        <population>The PK analysis set was defined as all participants who received at least one dose of study drug, who had no major protocol deviation, and whose PK data were evaluable.</population>
        <group_list>
          <group group_id="O1">
            <title>Study 2: TAK-438ASA Fasted</title>
            <description>TAK-438 10 mg and aspirin 100 mg FDC (TAK-438ASA), tablet, orally, under fasted condition, once on Day 1 of either Period 1 or 2.</description>
          </group>
          <group group_id="O2">
            <title>Study 2: TAK-438ASA Fed</title>
            <description>TAK-438 10 mg and aspirin 100 mg FDC (TAK-438ASA), tablet, orally, under fed condition, once on Day 1 of either Period 1 or 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Study 2, AUClast: Area Under the Plasma Concentration-time Curve From Time 0 to the Time of the Last Quantifiable Concentration for TAK-438F and Its Metabolites (M-I, M-II, M-III and M-IV-Sul)</title>
          <population>The PK analysis set was defined as all participants who received at least one dose of study drug, who had no major protocol deviation, and whose PK data were evaluable.</population>
          <units>h*ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>TAK-438F</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82.23" spread="16.775"/>
                    <measurement group_id="O2" value="102.4" spread="19.138"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M-I</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="258.6" spread="49.384"/>
                    <measurement group_id="O2" value="239.5" spread="44.950"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M-II</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.86" spread="12.921"/>
                    <measurement group_id="O2" value="20.66" spread="10.882"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M-III</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81.92" spread="15.032"/>
                    <measurement group_id="O2" value="78.69" spread="21.959"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M-IV-Sul</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="108.4" spread="36.884"/>
                    <measurement group_id="O2" value="89.48" spread="39.843"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>TAK-438F: The difference in the LSM between dosing condition (TAK-438ASA tablet taken in a fed [30 minutes after starting breakfast] - TAK-438ASA tablet taken in a fasted [without breakfast] condition) and the two-sided 90% CI were provided using a crossover ANOVA model. The ANOVA model included a log-transformed (natural log) analysis variable as the dependent variable, and dosing condition, sequence, and period as independent variables.</non_inferiority_desc>
            <param_type>LSM Difference</param_type>
            <param_value>0.2190</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.1675</ci_lower_limit>
            <ci_upper_limit>0.2706</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Study 2, Cmax: Maximum Observed Plasma Concentration for TAK-438F and Its Metabolites (M-I, M-II, M-III and M-IV-Sul)</title>
        <time_frame>Day 1 pre-dose and at multiple time points (up to 48 hours) post-dose</time_frame>
        <population>The PK analysis set was defined as all participants who received at least one dose of study drug, who had no major protocol deviation, and whose PK data were evaluable.</population>
        <group_list>
          <group group_id="O1">
            <title>Study 2: TAK-438ASA Fasted</title>
            <description>TAK-438 10 mg and aspirin 100 mg FDC (TAK-438ASA), tablet, orally, under fasted condition, once on Day 1 of either Period 1 or 2.</description>
          </group>
          <group group_id="O2">
            <title>Study 2: TAK-438ASA Fed</title>
            <description>TAK-438 10 mg and Aspirin 100 mg FDC (TAK-438ASA), tablet, orally, under fed condition, once on Day 1 of either Period 1 or 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Study 2, Cmax: Maximum Observed Plasma Concentration for TAK-438F and Its Metabolites (M-I, M-II, M-III and M-IV-Sul)</title>
          <population>The PK analysis set was defined as all participants who received at least one dose of study drug, who had no major protocol deviation, and whose PK data were evaluable.</population>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>TAK-438F</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.73" spread="2.5465"/>
                    <measurement group_id="O2" value="18.35" spread="5.4137"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M-I</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.26" spread="9.0261"/>
                    <measurement group_id="O2" value="35.22" spread="9.6886"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M-II</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.820" spread="0.83815"/>
                    <measurement group_id="O2" value="2.131" spread="0.57491"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M-III</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.38" spread="2.7078"/>
                    <measurement group_id="O2" value="14.90" spread="2.2273"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M-IV-Sul</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.52" spread="7.8634"/>
                    <measurement group_id="O2" value="23.09" spread="7.4466"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>TAK-438F: The difference in the LSM between dosing condition (TAK-438ASA tablet taken in a fed [30 minutes after starting breakfast] - TAK-438ASA tablet taken in a fasted [without breakfast] condition) and the two-sided 90% CI were provided using a crossover ANOVA model. The ANOVA model included a log-transformed (natural log) analysis variable as the dependent variable, and dosing condition, sequence, and period as independent variables.</non_inferiority_desc>
            <param_type>LSM Difference</param_type>
            <param_value>0.3653</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.2180</ci_lower_limit>
            <ci_upper_limit>0.5126</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Study 2, Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for TAK-438F and Its Metabolites (M-I, M-II, M-III and M-IV-Sul)</title>
        <time_frame>Day 1 pre-dose and at multiple time points (up to 48 hours) post-dose</time_frame>
        <population>The PK analysis set was defined as all participants who received at least one dose of study drug, who had no major protocol deviation, and whose PK data were evaluable.</population>
        <group_list>
          <group group_id="O1">
            <title>Study 2: TAK-438ASA Fasted</title>
            <description>TAK-438 10 mg and aspirin 100 mg FDC (TAK-438ASA), tablet, orally, under fasted condition, once on Day 1 of either Period 1 or 2.</description>
          </group>
          <group group_id="O2">
            <title>Study 2: TAK-438ASA Fed</title>
            <description>TAK-438 10 mg and aspirin 100 mg FDC (TAK-438ASA), tablet, orally, under fed condition, once on Day 1 of either Period 1 or 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Study 2, Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for TAK-438F and Its Metabolites (M-I, M-II, M-III and M-IV-Sul)</title>
          <population>The PK analysis set was defined as all participants who received at least one dose of study drug, who had no major protocol deviation, and whose PK data were evaluable.</population>
          <units>hour</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>TAK-438F</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.500" lower_limit="1.00" upper_limit="2.00"/>
                    <measurement group_id="O2" value="1.500" lower_limit="1.00" upper_limit="3.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M-I</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.500" lower_limit="1.00" upper_limit="1.50"/>
                    <measurement group_id="O2" value="1.500" lower_limit="1.00" upper_limit="4.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M-II</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.000" lower_limit="3.00" upper_limit="4.00"/>
                    <measurement group_id="O2" value="4.000" lower_limit="4.00" upper_limit="10.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M-III</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.750" lower_limit="1.00" upper_limit="2.00"/>
                    <measurement group_id="O2" value="2.000" lower_limit="1.00" upper_limit="4.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M-IV-Sul</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.500" lower_limit="1.00" upper_limit="3.00"/>
                    <measurement group_id="O2" value="2.000" lower_limit="1.50" upper_limit="4.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Study 2, T1/2z: Terminal Disposition Phase Half-life for TAK-438F and Its Metabolites (M-I, M-II, M-III and M-IV-Sul)</title>
        <time_frame>Day 1 pre-dose and at multiple time points (up to 48 hours) post-dose</time_frame>
        <population>The PK analysis set was defined as all participants who received at least one dose of study drug, who had no major protocol deviation, and whose PK data were evaluable. The PK analysis set where data at specified time points was available.</population>
        <group_list>
          <group group_id="O1">
            <title>Study 2: TAK-438ASA Fasted</title>
            <description>TAK-438 10 mg and aspirin 100 mg FDC (TAK-438ASA), tablet, orally, under fasted condition, once on Day 1 of either Period 1 or 2.</description>
          </group>
          <group group_id="O2">
            <title>Study 2: TAK-438ASA Fed</title>
            <description>TAK-438 10 mg and aspirin 100 mg FDC (TAK-438ASA), tablet, orally, under fed condition, once on Day 1 of either Period 1 or 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Study 2, T1/2z: Terminal Disposition Phase Half-life for TAK-438F and Its Metabolites (M-I, M-II, M-III and M-IV-Sul)</title>
          <population>The PK analysis set was defined as all participants who received at least one dose of study drug, who had no major protocol deviation, and whose PK data were evaluable. The PK analysis set where data at specified time points was available.</population>
          <units>hour</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>TAK-438F</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.293" spread="1.1254"/>
                    <measurement group_id="O2" value="7.951" spread="0.82489"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M-I</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.653" spread="1.3591"/>
                    <measurement group_id="O2" value="9.153" spread="1.0688"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M-II</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.92" spread="10.029"/>
                    <measurement group_id="O2" value="27.52" spread="38.721"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M-III</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.797" spread="2.1059"/>
                    <measurement group_id="O2" value="6.826" spread="1.5924"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M-IV-Sul</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.067" spread="1.4194"/>
                    <measurement group_id="O2" value="4.543" spread="1.6209"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Study 2, AUC∞: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for Unchanged Aspirin and Its Metabolite (Salicylic Acid)</title>
        <time_frame>Day 1 pre-dose and at multiple time points (up to 24 hours) post-dose</time_frame>
        <population>The PK analysis set was defined as all participants who received at least one dose of study drug, who had no major protocol deviation, and whose PK data were evaluable.</population>
        <group_list>
          <group group_id="O1">
            <title>Study 2: TAK-438ASA Fasted</title>
            <description>TAK-438 10 mg and aspirin 100 mg FDC (TAK-438ASA), tablet, orally, under fasted condition, once on Day 1 of either Period 1 or 2.</description>
          </group>
          <group group_id="O2">
            <title>Study 2: TAK-438ASA Fed</title>
            <description>TAK-438 10 mg and aspirin 100 mg FDC (TAK-438ASA), tablet, orally, under fed condition, once on Day 1 of either Period 1 or 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Study 2, AUC∞: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for Unchanged Aspirin and Its Metabolite (Salicylic Acid)</title>
          <population>The PK analysis set was defined as all participants who received at least one dose of study drug, who had no major protocol deviation, and whose PK data were evaluable.</population>
          <units>h*ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Unchanged aspirin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="817.9" spread="296.13"/>
                    <measurement group_id="O2" value="1008" spread="221.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Salicylic acid</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20010" spread="5299.3"/>
                    <measurement group_id="O2" value="20290" spread="5048.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>Unchanged aspirin: The difference in the LSM between dosing condition (TAK-438ASA tablet taken in a fed [30 minutes after starting breakfast] - TAK-438ASA tablet taken in a fasted [without breakfast] condition) and the two-sided 90% CI were provided using a crossover ANOVA model. The ANOVA model included a log-transformed (natural log) analysis variable as the dependent variable, and dosing condition, sequence, and period as independent variables.</non_inferiority_desc>
            <param_type>LSM Difference</param_type>
            <param_value>0.2089</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.0061</ci_lower_limit>
            <ci_upper_limit>0.4239</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>Salicylic acid: The difference in the LSM between dosing condition (TAK-438ASA tablet taken in a fed [30 minutes after starting breakfast] - TAK-438ASA tablet taken in a fasted [without breakfast] condition) and the two-sided 90% CI were provided using a crossover ANOVA model. The ANOVA model included a log-transformed (natural log) analysis variable as the dependent variable, and dosing condition, sequence, and period as independent variables.</non_inferiority_desc>
            <param_type>LSM Difference</param_type>
            <param_value>0.0140</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.0639</ci_lower_limit>
            <ci_upper_limit>0.0918</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Study 2, AUC(0-24): Area Under the Plasma Concentration-time Curve From Time 0 to Time 24 Hours Over the Dosing Interval for Unchanged Aspirin and Its Metabolite (Salicylic Acid)</title>
        <time_frame>Day 1 pre-dose and at multiple time points (up to 24 hours) post-dose</time_frame>
        <population>The PK analysis set was defined as all participants who received at least one dose of study drug, who had no major protocol deviation, and whose PK data were evaluable.</population>
        <group_list>
          <group group_id="O1">
            <title>Study 2: TAK-438ASA Fasted</title>
            <description>TAK-438 10 mg and aspirin 100 mg FDC (TAK-438ASA), tablet, orally, under fasted condition, once on Day 1 of either Period 1 or 2.</description>
          </group>
          <group group_id="O2">
            <title>Study 2: TAK-438ASA Fed</title>
            <description>TAK-438 10 mg and aspirin 100 mg FDC (TAK-438ASA), tablet, orally, under fed condition, once on Day 1 of either Period 1 or 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Study 2, AUC(0-24): Area Under the Plasma Concentration-time Curve From Time 0 to Time 24 Hours Over the Dosing Interval for Unchanged Aspirin and Its Metabolite (Salicylic Acid)</title>
          <population>The PK analysis set was defined as all participants who received at least one dose of study drug, who had no major protocol deviation, and whose PK data were evaluable.</population>
          <units>h*ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Unchanged aspirin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="816.7" spread="295.55"/>
                    <measurement group_id="O2" value="1007" spread="222.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Salicylic acid</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20070" spread="5318.8"/>
                    <measurement group_id="O2" value="20340" spread="5119.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>Unchanged aspirin: The difference in the LSM between dosing condition (TAK-438ASA tablet taken in a fed [30 minutes after starting breakfast] - TAK-438ASA tablet taken in a fasted [without breakfast] condition) and the two-sided 90% CI were provided using a crossover ANOVA model. The ANOVA model included a log-transformed (natural log) analysis variable as the dependent variable, and dosing condition, sequence, and period as independent variables.</non_inferiority_desc>
            <param_type>LSM Difference</param_type>
            <param_value>0.2099</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.0048</ci_lower_limit>
            <ci_upper_limit>0.4246</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>Salicylic acid: The difference in the LSM between dosing condition (TAK-438ASA tablet taken in a fed [30 minutes after starting breakfast] - TAK-438ASA tablet taken in a fasted [without breakfast] condition) and the two-sided 90% CI were provided using a crossover ANOVA model. The ANOVA model included a log-transformed (natural log) analysis variable as the dependent variable, and dosing condition, sequence, and period as independent variables.</non_inferiority_desc>
            <param_type>LSM Difference</param_type>
            <param_value>0.0137</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.0712</ci_lower_limit>
            <ci_upper_limit>0.0986</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Study 2, AUClast: Area Under the Plasma Concentration-time Curve From Time 0 to the Time of the Last Quantifiable Concentration for Unchanged Aspirin and Its Metabolite (Salicylic Acid)</title>
        <time_frame>Day 1 pre-dose and at multiple time points (up to 24 hours) post-dose</time_frame>
        <population>The PK analysis set was defined as all participants who received at least one dose of study drug, who had no major protocol deviation, and whose PK data were evaluable.</population>
        <group_list>
          <group group_id="O1">
            <title>Study 2: TAK-438ASA Fasted</title>
            <description>TAK-438 10 mg and aspirin 100 mg FDC (TAK-438ASA), tablet, orally, under fasted condition, once on Day 1 of either Period 1 or 2.</description>
          </group>
          <group group_id="O2">
            <title>Study 2: TAK-438ASA Fed</title>
            <description>TAK-438 10 mg and aspirin 100 mg FDC (TAK-438ASA), tablet, orally, under fed condition, once on Day 1 of either Period 1 or 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Study 2, AUClast: Area Under the Plasma Concentration-time Curve From Time 0 to the Time of the Last Quantifiable Concentration for Unchanged Aspirin and Its Metabolite (Salicylic Acid)</title>
          <population>The PK analysis set was defined as all participants who received at least one dose of study drug, who had no major protocol deviation, and whose PK data were evaluable.</population>
          <units>h*ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Unchanged aspirin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="816.5" spread="295.68"/>
                    <measurement group_id="O2" value="1007" spread="222.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Salicylic acid</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19370" spread="5108.5"/>
                    <measurement group_id="O2" value="19760" spread="4853.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>Unchanged aspirin: The difference in the LSM between dosing condition (TAK-438ASA tablet taken in a fed [30 minutes after starting breakfast] - TAK-438ASA tablet taken in a fasted [without breakfast] condition) and the two-sided 90% CI were provided using a crossover ANOVA model. The ANOVA model included a log-transformed (natural log) analysis variable as the dependent variable, and dosing condition, sequence, and period as independent variables.</non_inferiority_desc>
            <param_type>LSM Difference</param_type>
            <param_value>0.2096</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.0054</ci_lower_limit>
            <ci_upper_limit>0.4246</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>Salicylic acid: The difference in the LSM between dosing condition (TAK-438ASA tablet taken in a fed [30 minutes after starting breakfast] - TAK-438ASA tablet taken in a fasted [without breakfast] condition) and the two-sided 90% CI were provided using a crossover ANOVA model. The ANOVA model included a log-transformed (natural log) analysis variable as the dependent variable, and dosing condition, sequence, and period as independent variables.</non_inferiority_desc>
            <param_type>LSM Difference</param_type>
            <param_value>0.0201</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.0690</ci_lower_limit>
            <ci_upper_limit>0.1092</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Study 2, Cmax: Maximum Observed Plasma Concentration for Unchanged Aspirin and Its Metabolite (Salicylic Acid)</title>
        <time_frame>Day 1 pre-dose and at multiple time points (up to 24 hours) post-dose</time_frame>
        <population>The PK analysis set included all participants who received at least one dose of study drug, who had no major protocol deviation, and whose PK data were evaluable.</population>
        <group_list>
          <group group_id="O1">
            <title>Study 2: TAK-438ASA Fasted</title>
            <description>TAK-438 10 mg and aspirin 100 mg FDC (TAK-438ASA), tablet, orally, under fasted condition, once on Day 1 of either Period 1 or 2.</description>
          </group>
          <group group_id="O2">
            <title>Study 2: TAK-438ASA Fed</title>
            <description>TAK-438 10 mg and aspirin 100 mg FDC (TAK-438ASA), tablet, orally, under fed condition, once on Day 1 of either Period 1 or 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Study 2, Cmax: Maximum Observed Plasma Concentration for Unchanged Aspirin and Its Metabolite (Salicylic Acid)</title>
          <population>The PK analysis set included all participants who received at least one dose of study drug, who had no major protocol deviation, and whose PK data were evaluable.</population>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Unchanged aspirin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="632.5" spread="286.18"/>
                    <measurement group_id="O2" value="949.0" spread="415.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Salicylic acid</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4414" spread="930.76"/>
                    <measurement group_id="O2" value="5374" spread="1119.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>Unchanged aspirin: The difference in the LSM between dosing condition (TAK-438ASA tablet taken in a fed [30 minutes after starting breakfast] - TAK-438ASA tablet taken in a fasted [without breakfast] condition) and the two-sided 90% CI were provided using a crossover ANOVA model. The ANOVA model included a log-transformed (natural log) analysis variable as the dependent variable, and dosing condition, sequence, and period as independent variables.</non_inferiority_desc>
            <param_type>LSM Difference</param_type>
            <param_value>0.4058</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.0803</ci_lower_limit>
            <ci_upper_limit>0.7312</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>Salicylic acid: The difference in the LSM between dosing condition (TAK-438ASA tablet taken in a fed [30 minutes after starting breakfast] - TAK-438ASA tablet taken in a fasted [without breakfast] condition) and the two-sided 90% CI were provided using a crossover ANOVA model. The ANOVA model included a log-transformed (natural log) analysis variable as the dependent variable, and dosing condition, sequence, and period as independent variables.</non_inferiority_desc>
            <param_type>LSM Difference</param_type>
            <param_value>0.1969</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.1065</ci_lower_limit>
            <ci_upper_limit>0.2873</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Study 2, Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for Unchanged Aspirin and Its Metabolite (Salicylic Acid)</title>
        <time_frame>Day 1 pre-dose and at multiple time points (up to 24 hours) post-dose</time_frame>
        <population>The PK analysis set was defined as all participants who received at least one dose of study drug, who had no major protocol deviation, and whose PK data were evaluable.</population>
        <group_list>
          <group group_id="O1">
            <title>Study 2: TAK-438ASA Fasted</title>
            <description>TAK-438 10 mg and aspirin 100 mg FDC (TAK-438ASA), tablet, orally, under fasted condition, once on Day 1 of either Period 1 or 2.</description>
          </group>
          <group group_id="O2">
            <title>Study 2: TAK-438ASA Fed</title>
            <description>TAK-438 10 mg and aspirin 100 mg FDC (TAK-438ASA), tablet, orally, under fed condition, once on Day 1 of either Period 1 or 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Study 2, Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for Unchanged Aspirin and Its Metabolite (Salicylic Acid)</title>
          <population>The PK analysis set was defined as all participants who received at least one dose of study drug, who had no major protocol deviation, and whose PK data were evaluable.</population>
          <units>hour</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Unchanged aspirin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.500" lower_limit="2.00" upper_limit="6.00"/>
                    <measurement group_id="O2" value="4.000" lower_limit="2.50" upper_limit="7.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Salicylic acid</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.500" lower_limit="3.50" upper_limit="6.50"/>
                    <measurement group_id="O2" value="4.500" lower_limit="3.00" upper_limit="8.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Study 2, T1/2z: Terminal Disposition Phase Half-life for Unchanged Aspirin and Its Metabolite (Salicylic Acid)</title>
        <time_frame>Day 1 pre-dose and at multiple time points (up to 24 hours) post-dose</time_frame>
        <population>The PK analysis set was defined as all participants who received at least one dose of study drug, who had no major protocol deviation, and whose PK data were evaluable.</population>
        <group_list>
          <group group_id="O1">
            <title>Study 2: TAK-438ASA Fasted</title>
            <description>TAK-438 10 mg and aspirin 100 mg FDC (TAK-438ASA), tablet, orally, under fasted condition, once on Day 1 of either Period 1 or 2.</description>
          </group>
          <group group_id="O2">
            <title>Study 2: TAK-438ASA Fed</title>
            <description>TAK-438 10 mg and aspirin 100 mg FDC (TAK-438ASA), tablet, orally, under fed condition, once on Day 1 of either Period 1 or 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Study 2, T1/2z: Terminal Disposition Phase Half-life for Unchanged Aspirin and Its Metabolite (Salicylic Acid)</title>
          <population>The PK analysis set was defined as all participants who received at least one dose of study drug, who had no major protocol deviation, and whose PK data were evaluable.</population>
          <units>hour</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Unchanged aspirin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3749" spread="0.042784"/>
                    <measurement group_id="O2" value="0.4373" spread="0.10311"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Salicylic acid</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.050" spread="0.32982"/>
                    <measurement group_id="O2" value="1.901" spread="0.26555"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Study 2, Ae(0-48): Amount of Drug Excreted in Urine From Time 0 to 48 Hours for TAK-438F and Its Metabolites (M-I, M-II, M-III, and M-IV-Sul)</title>
        <time_frame>Day 1 pre-dose and at multiple time points (up to 48 hours) post-dose</time_frame>
        <population>The PK analysis set was defined as all participants who received at least one dose of study drug, who had no major protocol deviation, and whose PK data were evaluable.</population>
        <group_list>
          <group group_id="O1">
            <title>Study 2: TAK-438ASA Fasted</title>
            <description>TAK-438 10 mg and aspirin 100 mg FDC (TAK-438ASA), tablet, orally, under fasted condition, once on Day 1 of either Period 1 or 2.</description>
          </group>
          <group group_id="O2">
            <title>Study 2: TAK-438ASA Fed</title>
            <description>TAK-438 10 mg and aspirin 100 mg FDC (TAK-438ASA), tablet, orally, under fed condition, once on Day 1 of either Period 1 or 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Study 2, Ae(0-48): Amount of Drug Excreted in Urine From Time 0 to 48 Hours for TAK-438F and Its Metabolites (M-I, M-II, M-III, and M-IV-Sul)</title>
          <population>The PK analysis set was defined as all participants who received at least one dose of study drug, who had no major protocol deviation, and whose PK data were evaluable.</population>
          <units>microgram (mcg)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>TAK-438F</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="433.3" spread="63.305"/>
                    <measurement group_id="O2" value="583.1" spread="110.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M-I</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="150.1" spread="99.765"/>
                    <measurement group_id="O2" value="153.4" spread="61.628"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M-II</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.000" spread="0.0000"/>
                    <measurement group_id="O2" value="0.000" spread="0.0000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M-III</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.000" spread="0.0000"/>
                    <measurement group_id="O2" value="0.000" spread="0.0000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M-IV-Sul</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="237.0" spread="56.783"/>
                    <measurement group_id="O2" value="196.8" spread="59.876"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Study 2, Fe(0-48): Fraction of Administered Dose Excreted Into Urine From Time 0 to Time 48 Hours for TAK-438F and Its Metabolites (M-I, M-II, M-III and M-IV-Sul)</title>
        <time_frame>Day 1 pre-dose and at multiple time points (up to 48 hours) post-dose</time_frame>
        <population>The PK analysis set was defined as all participants who received at least one dose of study drug, who had no major protocol deviation, and whose PK data were evaluable.</population>
        <group_list>
          <group group_id="O1">
            <title>Study 2: TAK-438ASA Fasted</title>
            <description>TAK-438 10 mg and aspirin 100 mg FDC (TAK-438ASA), tablet, orally, under fasted condition, once on Day 1 of either Period 1 or 2.</description>
          </group>
          <group group_id="O2">
            <title>Study 2: TAK-438ASA Fed</title>
            <description>TAK-438 10 mg and aspirin 100 mg FDC (TAK-438ASA), tablet, orally, under fed condition, once on Day 1 of either Period 1 or 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Study 2, Fe(0-48): Fraction of Administered Dose Excreted Into Urine From Time 0 to Time 48 Hours for TAK-438F and Its Metabolites (M-I, M-II, M-III and M-IV-Sul)</title>
          <population>The PK analysis set was defined as all participants who received at least one dose of study drug, who had no major protocol deviation, and whose PK data were evaluable.</population>
          <units>percentage of dose</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>TAK-438F</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.333" spread="0.63305"/>
                    <measurement group_id="O2" value="5.831" spread="1.1083"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M-I</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.499" spread="0.99551"/>
                    <measurement group_id="O2" value="1.529" spread="0.61494"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M-II</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.000" spread="0.0000"/>
                    <measurement group_id="O2" value="0.000" spread="0.0000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M-III</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.000" spread="0.0000"/>
                    <measurement group_id="O2" value="0.000" spread="0.0000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M-IV-Sul</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.854" spread="0.44353"/>
                    <measurement group_id="O2" value="1.539" spread="0.46709"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Study 2, CLR: Renal Clearance for TAK-438F and Its Metabolites (M-I, M-II, M-III, and M-IV-Sul)</title>
        <time_frame>Day 1 pre-dose and at multiple time points (up to 48 hours) post-dose</time_frame>
        <population>The PK analysis set was defined as all participants who received at least one dose of study drug, who had no major protocol deviation, and whose PK data were evaluable.</population>
        <group_list>
          <group group_id="O1">
            <title>Study 2: TAK-438ASA Fasted</title>
            <description>TAK-438 10 mg and aspirin 100 mg FDC (TAK-438ASA), tablet, orally, under fasted condition, once on Day 1 of either Period 1 or 2.</description>
          </group>
          <group group_id="O2">
            <title>Study 2: TAK-438ASA Fed</title>
            <description>TAK-438 10 mg and aspirin 100 mg FDC (TAK-438ASA), tablet, orally, under fed condition, once on Day 1 of either Period 1 or 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Study 2, CLR: Renal Clearance for TAK-438F and Its Metabolites (M-I, M-II, M-III, and M-IV-Sul)</title>
          <population>The PK analysis set was defined as all participants who received at least one dose of study drug, who had no major protocol deviation, and whose PK data were evaluable.</population>
          <units>liter per hour (l/h)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>TAK-438F</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.213" spread="0.65760"/>
                    <measurement group_id="O2" value="5.604" spread="0.55389"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M-I</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5577" spread="0.38695"/>
                    <measurement group_id="O2" value="0.6018" spread="0.21705"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M-II</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.000" spread="0.0000"/>
                    <measurement group_id="O2" value="0.000" spread="0.0000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M-III</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.000" spread="0.0000"/>
                    <measurement group_id="O2" value="0.000" spread="0.0000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M-IV-Sul</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.148" spread="0.59016"/>
                    <measurement group_id="O2" value="2.126" spread="0.66434"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Study 2, Ae(0-24): Amount of Drug Excreted in Urine From Time 0 to 24 Hours for Unchanged Aspirin and Its Metabolites (Salicylic Acid and Salicyluric Acid)</title>
        <time_frame>Day 1 pre-dose and at multiple time points (up to 24 hours) post-dose</time_frame>
        <population>The PK analysis set was defined as all participants who received at least one dose of study drug, who had no major protocol deviation, and whose PK data were evaluable.</population>
        <group_list>
          <group group_id="O1">
            <title>Study 2: TAK-438ASA Fasted</title>
            <description>TAK-438 10 mg and aspirin 100 mg FDC (TAK-438ASA), tablet, orally, under fasted condition, once on Day 1 of either Period 1 or 2.</description>
          </group>
          <group group_id="O2">
            <title>Study 2: TAK-438ASA Fed</title>
            <description>TAK-438 10 mg and aspirin 100 mg FDC (TAK-438ASA), tablet, orally, under fed condition, once on Day 1 of either Period 1 or 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Study 2, Ae(0-24): Amount of Drug Excreted in Urine From Time 0 to 24 Hours for Unchanged Aspirin and Its Metabolites (Salicylic Acid and Salicyluric Acid)</title>
          <population>The PK analysis set was defined as all participants who received at least one dose of study drug, who had no major protocol deviation, and whose PK data were evaluable.</population>
          <units>mcg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Unchanged aspirin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="481.3" spread="173.04"/>
                    <measurement group_id="O2" value="817.3" spread="403.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Salicylic acid</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2318" spread="1904.7"/>
                    <measurement group_id="O2" value="2076" spread="1159.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Salicyluric acid</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80180" spread="9852.2"/>
                    <measurement group_id="O2" value="83800" spread="4019.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Study 2, Fe(0-24): Fraction of Administered Dose Excreted Into Urine From Time 0 to Time 24 Hours for Unchanged Aspirin and Its Metabolites (Salicylic Acid and Salicyluric Acid)</title>
        <time_frame>Day 1 pre-dose and at multiple time points (up to 24 hours) post-dose</time_frame>
        <population>The PK analysis set was defined as all participants who received at least one dose of study drug, who had no major protocol deviation, and whose PK data were evaluable.</population>
        <group_list>
          <group group_id="O1">
            <title>Study 2: TAK-438ASA Fasted</title>
            <description>TAK-438 10 mg and aspirin 100 mg FDC (TAK-438ASA), tablet, orally, under fasted condition, once on Day 1 of either Period 1 or 2.</description>
          </group>
          <group group_id="O2">
            <title>Study 2: TAK-438ASA Fed</title>
            <description>TAK-438 10 mg and aspirin 100 mg FDC (TAK-438ASA), tablet, orally, under fed condition, once on Day 1 of either Period 1 or 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Study 2, Fe(0-24): Fraction of Administered Dose Excreted Into Urine From Time 0 to Time 24 Hours for Unchanged Aspirin and Its Metabolites (Salicylic Acid and Salicyluric Acid)</title>
          <population>The PK analysis set was defined as all participants who received at least one dose of study drug, who had no major protocol deviation, and whose PK data were evaluable.</population>
          <units>percentage of dose</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Unchanged aspirin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4813" spread="0.17304"/>
                    <measurement group_id="O2" value="0.8173" spread="0.40378"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Salicylic acid</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.025" spread="2.4834"/>
                    <measurement group_id="O2" value="2.708" spread="1.5127"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Salicyluric acid</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74.02" spread="9.0984"/>
                    <measurement group_id="O2" value="77.34" spread="3.7218"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Study 2, CLR: Renal Clearance for Unchanged Aspirin and Its Metabolites (Salicylic Acid and Salicyluric Acid)</title>
        <time_frame>Day 1 pre-dose and at multiple time points (up to 24 hours) post-dose</time_frame>
        <population>The PK analysis set was defined as all participants who received at least one dose of study drug, who had no major protocol deviation, and whose PK data were evaluable. Data for CLR of Salicyluric acid was not calculated since the plasma concentration of Salicyluric acid was not measured.</population>
        <group_list>
          <group group_id="O1">
            <title>Study 2: TAK-438ASA Fasted</title>
            <description>TAK-438 10 mg and aspirin 100 mg FDC (TAK-438ASA), tablet, orally, under fasted condition, once on Day 1 of either Period 1 or 2.</description>
          </group>
          <group group_id="O2">
            <title>Study 2: TAK-438ASA Fed</title>
            <description>TAK-438 10 mg and aspirin 100 mg FDC (TAK-438ASA), tablet, orally, under fed condition, once on Day 1 of either Period 1 or 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Study 2, CLR: Renal Clearance for Unchanged Aspirin and Its Metabolites (Salicylic Acid and Salicyluric Acid)</title>
          <population>The PK analysis set was defined as all participants who received at least one dose of study drug, who had no major protocol deviation, and whose PK data were evaluable. Data for CLR of Salicyluric acid was not calculated since the plasma concentration of Salicyluric acid was not measured.</population>
          <units>l/h</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Unchanged aspirin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.6181" spread="0.28917"/>
                    <measurement group_id="O2" value="0.7818" spread="0.29682"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Salicylic acid</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1135" spread="0.083534"/>
                    <measurement group_id="O2" value="0.1022" spread="0.055826"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Treatment-emergent adverse events are adverse events (AE) that started after the first dose of study drug and no more than 2 days after the last dose of study drug in Period 2 (Day 18)</time_frame>
      <desc>At each visit the investigator had to document any occurrence of adverse events and abnormal laboratory findings. Any event spontaneously reported by the participant or observed by the investigator was recorded, irrespective of the relation to study treatment. Two participants discontinued the study due to an AE in Period 2 pre-dose and did not receive the study drug for Period 2.</desc>
      <group_list>
        <group group_id="E1">
          <title>Pilot Study 1: TAK-438ASA</title>
          <description>TAK-438 10 mg and aspirin 100 mg FDC (TAK-438ASA), tablet, orally, under fasted condition, once on Day 1 of either Period 1 or 2.</description>
        </group>
        <group group_id="E2">
          <title>Pilot Study 1: TAK-438 and Aspirin</title>
          <description>TAK-438 10 mg, tablet and aspirin 100 mg, tablet (free combination), orally, under fasted condition, once on Day 1 of either Period 1 or 2.</description>
        </group>
        <group group_id="E3">
          <title>Pivotal Study 1: TAK-438ASA</title>
          <description>TAK-438 10 mg and aspirin 100 mg FDC (TAK-438ASA), tablet, orally, under fasted condition, once on Day 1 of either Period 1 or 2.</description>
        </group>
        <group group_id="E4">
          <title>Pivotal Study 1: TAK-438 and Aspirin</title>
          <description>TAK-438 10 mg, tablet and aspirin 100 mg, tablet (free combination), orally, under fasted condition, once on Day 1 of either Period 1 or 2.</description>
        </group>
        <group group_id="E5">
          <title>Study 2: TAK-438ASA Fasted</title>
          <description>TAK-438 10 mg and aspirin 100 mg FDC (TAK-438ASA), tablet, orally, under fasted condition, once on Day 1 of either Period 1 or 2.</description>
        </group>
        <group group_id="E6">
          <title>Study 2: TAK-438ASA Fed</title>
          <description>TAK-438 10 mg and aspirin 100 mg FDC (TAK-438ASA), tablet, orally, under fed condition, once on Day 1 of either Period 1 or 2.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA (21.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="237"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="239"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="237"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="239"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="237"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Liver function test abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Research Organization shall not publish any articles or papers nor make any presentations, nor assist any other person in publishing any articles or papers or in making any presentations relating or referring to the Study or any results, data or insights from or any data, information or materials obtained or generated in the performance of its obligations without the prior written consent of Takeda, which consent may be granted or withheld in Takeda’s sole discretion.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Medical Director</name_or_title>
      <organization>Takeda</organization>
      <phone>+1-877-825-3327</phone>
      <email>trialdisclosures@takeda.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

